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ABSTRACT 
 
Some studies suggest that lung tumour cell ontogeny is determined by 
consequences of gene expression that recapitulate important events in embryonic lung 
development. Hypoxia plays a crucial role either in physiological or pathological 
conditions such in tumour growth, and in embryonic and fetal development, being one of 
the most important extracellular factors for lung morphogenesis. In order to adapt to 
environmental hypoxia, cells rely on anaerobic glycolysis, resulting in increased 
production of acids, mostly lactic acid. Some studies demonstrated that the control of 
intracellular pH (pHi) could be carried out by a family of transporters which are H+-
monocarboxylate co-transporters, known as monocarboxylate transporters (MCTs). These 
studies show evidence for the expression of MCTs during early development of human 
and mouse embryos and in embryo pre-implantation.  
As in embryonic development, tumour cells take advantage of MCTs to maintain 
tumour intracellular pH, by promoting the efflux of accumulating acids. There are studies 
showing the upregulation of MCTs in several solid tumours such as colorectal 
carcinomas, cervix carcinoma and breast tumours. Regarding lung tumours the results 
published so far are controversial.  
MCT family comprises 14 members however only MCT1-MCT4 are proton 
symporters that exhibit different affinities for lactate, leading to different levels of tissue 
expression. Ancillary protein, named CD147 is required to maintain the catalytic activity 
of and the translocation to the plasma membrane of MCT1 and MCT4.  
Since tumourigenesis and embryogenesis exhibit some common features, such as 
low oxygen availability, this work aims to study and characterize the role of MCTs both 
in lung development and lung cancer and thus seek for the metabolic adaptations common 
to both embryo and tumour development.  
In lung development, MCT1, MCT4 and CD147 expression was evaluated during 
human and rat fetal lung development and the effect of MCT inhibition was evaluated on 
the morphogenesis of rat fetal lung explants. Importantly, MCT1, MCT4 and CD147 
were differently expressed during the different phases of lung development suggesting 
that these molecules are important for lung morphogenesis. Moreover we exposed rat 
fetal lung explants to the MCT inhibitor CHC and we observed an inhibitory effect on 
lung branching and viability, in a dose dependent way. 
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Moreover, in lung cancer, MCT1, MCT4 and CD147 were evaluated in a human 
lung cancer series and in order to understand the influence of MCTs inhibition in lung 
cancer we disrupted CD147 using the zinc finger technology. The effect the knockout 
(KO) of CD147 was evaluated using in vitro and in vivo models. 
Regarding lung cancer, MCT1, MCT4 and CD147 were upregulated in tumour 
samples when compared with non-tumoural adjacent tissue. With the KO of CD147 we 
decreased the expression and activity of MCT1 and MCT4. Moreover, the clonal growth 
of KO cells is inhibited in vitro after oxidative phosphorylation (OXPHOS) inhibition 
with phenformin and we observed a more pronounced decrease in tumour growth in vivo 
of KO cells to the treatment with phenformin. 
To conclude, this study suggests that MCTs are important molecules in the 
physiology of lung development and provide evidence supporting the exploitation of 
MCTs/CD147 as therapeutic targets. However, further studies, particularly using specific 
MCTs/CD147 blockers are urgently needed.  
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RESUMO 
 
Alguns estudos sugerem que a ontogenia das células tumorais do pulmão é 
determinada por consequências na expressão genética que recapitulam eventos 
importantes do desenvolvimento embrionário do pulmão. A hipóxia tem um papel crucial 
tanto em condições fisiológicas como patológicas no crescimento tumoral e no 
desenvolvimento embrionário e fetal, sendo um dos factores extracelulares importante na 
morfogéneses do pulmão. Para se adaptarem ao ambiente de hipoxia, as células dependem 
da glicólise anaeróbica resultando num aumento da produção de ácidos; nomeadamente 
acido láctico. Alguns estudos demonstram que o controlo do pH intracelular (pHi) pode 
ser realizado por uma família de transportadores denominados Transportadores de 
Monocarboxilatos MCTs. Estes estudos mostram evidências para a expressão dos MCTs 
durante o desenvolvimento precoce do embrião humana e de ratinho e também na pré-
implantação do embrião.  
Tal como no desenvolvimento embrionário, as células tumorais utilizam os MCTs 
para manter o pHi tumoral, promovendo o efluxo de ácidos acumulados. Há estudos que 
demonstram o aumento de expressão dos MCTs em diversos tumores sólidos, tais como 
carcinomas colo-rectal, carcinoma do colo-uterino e tumores mamários. Quanto aos 
tumores de pulmão, os resultados obtidos até agora são controversos. 
A família dos MCTs engloba 14 membros no entanto, apenas MCT1-MCT4 são 
transportadores de protões e apresentam afinidades diferentes para o lactato, levando a 
diferentes níveis de expressão tecidual. A proteína auxiliar, denominada CD147 é 
necessária para manter a atividade catalítica e a translocação para a membrana plasmática 
do MCT1 e do MCT4.  
Uma vez que a tumorigênese e embriogénese apresentam algumas características 
comuns, como o baixo teor em oxigênio, este trabalho tem como objetivo estudar e 
caracterizar o papel dos MCTs, tanto no desenvolvimento pulmonar como em cancro do 
pulmão e, assim, identificar as adaptações metabólicas comuns a ambos os processos.  
No desenvolvimento pulmonar, a expressão do MCT1, MCT4 e CD147 foi 
avaliada durante em pulmão fetal humano e de rato e o efeito da inibição dos MCTs foi 
avaliada na morfogénese pulmonar usando explantes pulmonares fetais de ratinho. 
MCT1, MCT4 e CD147 foram diferencialmente expressos durante as diferentes fases do 
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desenvolvimento pulmonar, sugerindo que estas moléculas são importantes para a 
morfogênese de pulmão. Além disso,  após a exposição dos explantes pulmonares fetais 
de rato ao inibidor dos MCTs, o CHC, observamos um efeito inibitório na viabilidade e 
ramificação do pulmão, de um modo dependente da dose. 
Além disso, no cancro do pulmão, o MCT1, o MCT4 e a CD147 foram avaliados 
numa série de cancro de pulmão humano e a fim de compreender o efeito da inibição dos 
MCTs, inibimos a CD147 utilizando a tecnologia de “zinc finger”. O efeito do knock-out 
(KO) da CD147 foi avaliada em modelos in vitro e in vivo. 
Neste modelo observamos a sobre-expressão do MCT1, do MCT4 e da CD147 
nas células tumorais, quando comparado com o tecido adjacente não-tumoral. Com o KO 
da CD147 verificamos a diminuição da expressão e da atividade do MCT1 do MCT4. 
Estudos in vitro demonstraram que após a inibição da fosforilação oxidativa com a 
fenformina o crescimento clonal das células negativas para a CD147 foi inibido e para 
além disso observamos uma diminuição mais acentuada no crescimento tumoral destas 
celulas in vivo após tratamento com a mesma droga.  
Em termo de conclusão, este estudo sugere que os MCTs são moléculas 
importantes na fisiologia do desenvolvimento pulmonar e fornece evidências que 
suportam a exploração dos MCTs/CD147 como alvos terapêuticos. No entanto, são 
urgentemente necessários mais estudos, principalmente utilizando inibidores específicos 
para MCTs/CD147  
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AIMS AND THESIS LAYOUT  
 
AIMS  
 
It is suggested that gene expression in lung tumour cells recapitulate important 
events in embryonic lung development. Hypoxia is a common event in both conditions 
where cells rely on anaerobic metabolism for energy supply, leading to intracellular 
accumulation of acids. These acids have an important role in cell metabolism and their 
rapid transport across the plasma membrane is crucial for the maintenance of intracellular 
pH homeostasis. This transport is mediated by a family of transporters, designated by 
Monocarboxylate Transporters (MCTs), namely isoforms 1-4. Studies on MCTs 
contribution to lung development are still scarce and for the malignant behavior of a 
tumour cell is not really elucidated. Thus, more basic scientific efforts on this matter are 
needed, which will probably result in important findings, with clinical implications. 
Therefore, the general aim of this thesis was to contribute to a better understand 
of the role of MCTs in both lung development and lung cancer. 
 
THESIS LAYOUT 
 
The present thesis is organized in 4 different chapters: 
 
Chapter 1 contains a general introduction on the subject of the thesis. It is 
presented a briefly introduction on embryo and cancer cell metabolism with special 
emphasis on MCT family members. 
 
Chapter 2 presents the study on MCTs in lung embryo. In this study we describe 
a complete characterization of the expression pattern of MCTs in human fetal lung 
development and we explore the effect of MCTs inhibition in rat fetal lung explant 
cultures. 
 
Chapter 3 presents the study on MCTs in lung cancer. The current knowledge on 
MCT contribution to tumour microenvironment, lactate production and its contribution to 
the malignant phenotype and the potential of MCTs/CD147 as targets in cancer therapy 
Aims and thesis layout 	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are also reviewed. This study reports the expression of MCTs in lung cancer samples, and 
their biological effect in lung tumourigenesis assessed by in vitro and in vivo experiments.   
 
Chapter 4 is the last chapter where a general discussion of the thesis is presented 
as well as the final conclusions of the work. 
 
	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: General Introduction 
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1.1 Cell metabolism 
 
Metabolism impacts all cellular functions and plays a fundamental role in 
biology. Lately there has risen a great interest in cell metabolism and its involvement 
in several pathways. Metabolic requirements of each cell type are determined by their 
tissue function and microenvironment as nutrient availability and oxygen levels 1.  
 
 
 
Metabolic pathways are well conserved among eukaryotes, where organisms 
use both glycolytic and mitochondrial metabolism depending on extracellular 
conditions, cues and cellular needs 2. Glycolysis, occurs by the Embden-Meyerhof 
pathway and involves a series of cytoplasmatic enzymes that converts glucose into 
pyruvate 3. Then, pyruvate enters the mitochondria to be oxidized by the Krebs cycle. 
These two processes in sequence generate the equivalent of 36 ATP units per glucose 
molecule (Figure 1) 4,5.  
Figure 1: Cell respiration in eukaryotic cell in normal physiologic conditions 5. Illustrative scheme of 
glycolysis, tricarboxylic acid (TCA) cycle, and the electron transport chain. Briefly glucose is converted 
into pyruvate, generating 2 molecules of ATP per glucose. Pyruvate is then oxidized into Acetyl-CoA, 
which enters the mitochondrial TCA cycle. The NADH generated is then fed into the oxidative 
phosphorylation pathway producing 36 molecules of ATP. 
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Such is the energetic fate of glucose in healthy tissue under normal 
physiological conditions. Under anaerobic conditions, where oxygen is limited, 
glycolysis may be the main energy source of an organism. Cells are able to switch 
from a state of low energy production that maintain basal functions to a state of 
activation of anabolic pathways to rapidly grow and proliferate 1. More specifically, 
the differences in aerobic and anaerobic respiration depend on the different roles 
played by the NADH molecules produced. In both aerobic and anaerobic respiration, 
NADH must be restored to its oxidized state (NAD+). Under aerobic conditions, 
meaning oxygen availability, NADH can be transported into the mitochondria where 
it can be immediately reoxidized to NAD, playing a role in the electron transport 
chain. However, under anaerobic conditions, NADH is reoxidized to NAD through 
anaerobic mechanisms, either by homolactic or alcoholic fermentation. Pyruvate, 
product of glycolysis, is converted into lactic acid by the enzyme lactate 
dehydrogenase (LDH). In this reaction, the hydrogen from NADH molecule is 
transferred to the pyruvate molecule, leading to production of lactate. From the lactate 
product, lactic acid can be formed. These anaerobic conditions lead to glycolytic 
products other than pyruvate. These different products are necessary for NADH 
reoxidization so that it allows the next round of glycolysis (Figure 2) 6.  
 
 
Several systems control and modulate metabolic flux in a cell such as 
hormones, small macromolecules and/or other extracellular factors that have an effect 
in different enzymes. AMP-activated protein kinase (AMPK) is a sensor that 
	  
Figure 2: Anaerobic glycolysis. In the absence of oxygen, pyruvate is converted to lactate via 
lactate dehydrogenase A (LDH-A) 5. This reaction allows the cell to regenerate NAD to continue 
glycolysis 5. 
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coordinates diverse metabolic responses 7. AMPK acts as a metabolic master switch 
regulating several intracellular systems including the cellular uptake of glucose, the β-
oxidation of fatty acids and the biogenesis of glucose transporter 4 (GLUT4) and 
mitochondria 8. The energy-sensing capability of AMPK can be attributed to its 
ability to detect and react to fluctuations in AMP: ATP ratio that takes place during 
rest and exercise 9. Upon activation, AMPK increases cellular energy levels by 
inhibiting anabolic energy consuming pathways, such as fatty acid synthesis and 
protein synthesis and stimulating energy producing, catabolic pathways as fatty acid 
oxidation, glucose transport and others 4,10. 
Low oxygen concentrations also control and induce a whole spectrum of 
cellular and systemic responses 11,12. The oxygen level in the cells and organs is 
regulated by pathways that affect the expression and activity of numerous cellular 
proteins 13. Sensing and responding alterations in oxygen tension are important 
variations in the physiology, and tissues have developed essential mechanisms of 
response to physiological oxygen reduction 14. Hypoxia is commonly associated with 
pathologies such as tissue ischaemia and inflammation. However, hypoxic 
microenvironments also occur in both the developing embryo and the adult, and often 
create specific niches that regulate cellular differentiation 13,15. Molecular mechanisms 
through which O2 levels interfere with cell physiology have been elucidated by the 
characterization of hypoxia inducible factors (HIFs), which are dimeric transcription 
factors that regulate hypoxic responses in cells and tissues 11,16. HIF-1 is considered a 
master switch that allows cells to respond to falling oxygen levels. The protein 
consists of two essential subunits, HIF-1α and HIF-1β, which heterodimerize 11, 
whereas HIF-1β is constitutively expressed, HIF-1α expression is induced in hypoxic 
cells with an exponential increase in expression as cells are exposed to O2 
concentrations of less than 6% 11. The amino-terminal half of each subunit contains 
basic helix-loop-helix (bHLH) and PER-ARNT-SIM homology (PAS) domains 16. 
The mechanism by which hypoxia increase HIF-1 activity was just discovered when 
evidence showed that HIF-1α ubiquitination required hydroxylation at two proline 
residues, which are Pro-402 and Pro-564 in human HIF-1α. Under normoxic 
conditions, hydroxylation of HIF-1 α is catalyzed by prolyl hydroxylase domain 
proteins (PHDs) using O2 as substrate 17. When O2 is low, PHD activity decreases and 
hydroxylation of HIF-1α at the proline residues also decreases, resulting in protein 
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stabilization. HIF-1α then translocates into the nucleus, where it binds HIF-1β and 
recruits coactivator proteins to the HIF binding site within the hypoxia response 
element (HRE), activating the transcription of various target genes 18,19. Many genes 
are transcriptionally activated by HIF-1 in response to hypoxia, such as glucose 
transporters, glycolytic enzymes, and vascular endothelial growth factor (VEGF) for 
angiogenesis 20. 
Nutrient availability also control and influence cell metabolism. For cells 
inserted in an environment with glucose limitation, one known adaptation is to 
decrease glucose oxidation and utilize amino acids, fatty acids or lipids. 
 
 
1.2 Embryogenesis vs tumorigenesis: cellular metabolism 
 
1.2.1 Embryo metabolism 
There still seems to be a controversy as to whether the developing embryo 
relies on glycolysis or respiration.  
 Embryonic and fetal development is strongly influenced by the levels of 
oxygen in the environment 21,22. Studies related to placenta formation indicate that the 
human embryo and human placenta develop in a hypoxic environment during the first 
trimester. The placenta consists of a gestational sac, villi with few capillaries, a 
trophoblast layer and an exocoelomic cavity which does not contain oxygen transport 
system but the anti-oxidant molecules present protect the embryo from oxidative 
damage. Thus, these features are indirect evidence that the gestational sac limits the 
embryonic oxygen exposure 14,23. Also, studies of metabolism in various stem cell 
populations have also highlighted a role for cell-specific metabolic pathways that are 
modulated during differentiation 24. Some authors suggest that the initial low hypoxia 
levels normally present within the heart fields and neural tissue activate HIF1-
inducible genes for normal development 14. 
The fundamental effects of oxygen levels on embryo development, 
physiology, and disease pathophysiology are now being unveilled. It seems that the 
development of the embryo takes place in a physiologically low oxygen environment 
and energy demands rely on glycolysis 14,25. However, studies indicate that 
metabolism is tightly controlled by glycolytic enzymes such as hexokinase (HK) and 
phosphofructokinase 1 (PFK1), thus glycolysis rates are initially low 26. Thus, the 
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only energy and carbon sources are pyruvate analogs (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In fact, early embryo development is actually inhibited by high concentrations 
of glucose 24. Thus, pre-implantation embryos in vivo develop in uterine fluid and 
derive their ATP predominantly from oxidative metabolism of pyruvate, lactate, and 
amino acids. The oxidation of pyruvate in mitochondria then fuels the Krebs cycle, 
which in turn generates carbon intermediates and fuels oxidative phosphorylation 
(OXPHOS). Therefore, pyruvate has the ability to react with hydrogen peroxide 27 
and/or may serve as means of removing ammonia from the embryo, converting it into 
alanine 28. The embryo only becomes more dependent on aerobic glycolysis after 
implantation, at the morula stage 25,29. During this stage, there is an increase in growth 
and metabolic activity. Cells upregulate the expression of glucose transporters as 
GLUT1 and GLUT3 30. The glycolytic flux increase, leading to a higher synthesis of 
lactate 31. The importance of glycolysis to blastocysts is evident in vivo, as mutations 
Figure 3: Metabolism in embryonic cells; Energy and carbon source are obtained by oxidative metabolism 
of pyruvate and lactate 24.  Ac- CoA, acetyl coenzyme A; HK, hexokinase; F6P, fructose-6-phosphate; FBP, 
fructose-1,6- bisphosphate; G6P, glucose-6-phosphate; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; LDHA, lactate dehydrogenase A; OAA, oxaloacetate; OxPhos, oxidative phosphorylation; 
PDH, pyruvate dehydrogenase complex; PFK1, phosphofructokinase 1; TPI1, triosephosphate isomerase. 
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in four glycolytic enzymes as glucose-6-phosphate isomerase, glyceraldehyde-3-
phosphate dehydrogenase, triosephosphate isomerase and lactate dehydrogenase A 
(LDH-A) result in early post-implantation lethality 24,32–34. The mouse embryos at 
gestational day 6.5–9.5 that grow in vitro convert 90% of the catabolized glucose to 
lactate, even though the embryos are cultured in 20% oxygen, which should favour 
oxidative pathways 35. For rat and mouse embryos, it appears that for the start of the 
organogenic period, including the period of neural tube closure, the embryo is largely 
dependent on glycolysis even when conditions favour more efficient pathways 36,37. 
However, the availability of oxygen to the embryo in vivo is not really known 22. 
Lactate formed by early human embryos derived from pyruvate 38 and its 
exchange with the extracellular space, seems to be important for the regulation of the 
intracellular pH (pHi) and / or to maintain the NAD+/NADH ratio39. Cellular function 
depends on its energetic metabolism, and metabolism generates intracellular acid by 
the formation of H+
 
ions. The ability of cells to control their ionic composition in 
response to external ionic stress is, therefore, likely to be an important determinant of 
the developmental progress, but there is limited knowledge on the ion transporters and 
channels at these early stages of development 29. For example, H+
 
ions can exert 
particularly powerful influences on cell function, and so understanding the nature and 
properties of the proton transport and buffering systems available to the conceptus is 
of particular significance 40,41. The pHi may also play a role in developmental 
signalling. It has been described as an important trigger for the later developmental 
events of neural induction and posterior axial 42. The importance of the pHi for 
successful early development was first demonstrated empirically in Bavister’s studies 
on the pH dependence of monospermic fertilization in the hamster 43. Cells regulate 
pHi through exchangers on the plasma membrane. These transports include the 
Na+/H+
 
exchanger, Na+, HCO3-/Cl-
 
exchanger, however, the mechanism of pHi 
regulation during embryo development is not really elucidated 44. Posterior studies 
demonstrated that control of pHi could be also carried out by a family of transporters 
designated by H+-monocarboxylate co-transporters (MCTs). 
 
1.2.2 Cancer metabolism 
 Targeting metabolic pathways in cancer has been an interesting area of 
research and has been the subject of study of several groups in the last decades. 
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Cancer cells have a higher demand for metabolic energy to grow and survive, thus 
studying cancer cell metabolism and the interplay between metabolic pathways 
contribute to a better knowledge in tumourigenesis 1.     
 Changes in nutrient metabolism are critical parts of tumour suppressor and 
oncogene networks to support cancer development 45. Enhanced glucose uptake is 
observed in several tumours, being a significant fraction of glucose metabolized 
through glycolysis. Glucose-derived pyruvate can enter mitochondria to fuel the 
tricarboxylic acid (TCA) cycle, but in many cancer cells, a significant fraction of 
glucose ends up as lactate instead, a phenomenon known as aerobic glycolysis, since 
it occurs independently of the presence of oxygen. 
 
 
This increase in glucose uptake and conversion to lactate in the presence of 
oxygen is also known as “Warburg effect”.  Otto Warburg, a pioneer in the study of 
respiration, made a huge discovery in the 1920s. He found that, even in the presence 
of oxygen, cancer cells prefer to metabolize glucose by glycolysis a less efficient 
pathway for producing ATP when compared to oxidative phosphorylation (Figure. 4) 
46. The Warburg effect has since been demonstrated in different types of tumours and 
Figure 4: The Warburg effect or aerobic glycolysis 1; Tumour/proliferative cells predominantly produce 
energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a 
comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most 
normal cells.   
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the concomitant increase in glucose uptake has been exploited clinically for the 
detection of tumours by fluorodeoxyglucose positron emission tomography (FDG-
PET) and also for an early indicator of drug efficacy (Figure 5) 47.  
Although aerobic glycolysis has been introduced as a hallmark of cancer 48, its 
relationship with cancer progression can vary among tumours. The Warburg effect, 
meaning the switch of metabolism to glycolysis confers numerous advantages to 
cancer cells. For example, glycolysis alone produces ATP more rapidly than 
glycolysis coupled with OXPHOS and generates carbon intermediates used in 
biosynthetic pathways 49,50. 
 
 
 
 
 
 
 
 
 
 
The upregulation of glycolysis triggers the accumulation of pyruvate and 
production of lactate 51, which results in an acidic microenvironment that also confers 
a selective advantage to cancer cells, being harmless for them but fatal to normal cells 
52,53. A low extracellular pH (pHe) together with hypoxia results in a escape to cell 
death through activation of intracellular pathways, for example the extracellular-
signal-related kinase (ERK1/2) 54. This pathway is involved in the activation of 
several cell phenotypes as proliferation, transformation, tumourigenesis, invasion, 
angiogenesis, differentiation and survival 55. In fact, experiments demonstrate that the 
acidic pH upregulate the phosphorylation of ERK1/2 56. Thus, altogether, the 
activation of ERK1/2, acidification and hypoxia also lead to the increased release and 
Figure 5: Positron-emission tomography (PET) imaging 
with 18 fluorodeoxyglucose (FDG) 52. Analysis of a patient 
with lymphoma. The mediastinal nodes (purple arrow) and 
supraclavicular nodes (green arrows) show high uptake of 
FDG showing that this tumours have a high uptake of 
glycolysis. The bladder (yellow arrow) also has high 
activity, because of excretion of the radionuclide.  
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activation of acidic proteases such as cathepsin B 57, MMP2 and MMP9 54,58 which 
are expressed in the extracellular matrix (ECM) of the tumour and promotes its 
degradation leading to invasion and metastasis 59. The vascular endothelial growth 
factor (VEGF) is also upregulated inducing angiogenesis 60. Moreover, pyruvate 
accumulation is redirected to lipids synthesis and OXPHOS decrease leads to citrate 
accumulation that will serve to promote fatty acid and cholesterol synthesis 50. In 
some tumour cells, the utilization of the pentose phosphate pathway (PPP) is also 
reported to produce ribose and NADPH for de novo nucleic acid synthesis. 
As the tumour starts to grow, the oxygen diffusion becomes limited, thus cells 
must sense and respond to these environmental changes 61. HIF initiates a 
transcriptional program that provides multiple solutions to hypoxic stress. HIF 
induces the up-regulation of glucose transporters such as GLUT1 and GLUT3 during 
carcinogenesis of several tumours 62. Also, it induces the expression of glycolytic 
enzymes as hexokinase II and LDH-A 63,64. HIF also prevents the entry of pyruvate 
into the TCA cycle by inducing pyruvate dehydrogenase kinase 1 (PDK1) 65 driving 
tumour cell energy dependence mainly to glycolysis 53. In addition, HIF induces 
angiogenesis by overexpression of angiogenenic factors such as VEGF 61,66. The 
tumour recruits blood vessels creating a disorganized and often non-functional 
network that results in a microenvironment with fluctuating areas of oxygen and 
therefore with upregulation of glycolysis 61,67,68. 
Besides HIF, there are other molecular mechanisms that are equally important 
and involved in metabolic changes inside a tumour. Several studies have 
demonstrated that the decrease of oxidative phosphorylation, the increase in glucose 
consumption and lactate production can also be driven by oncogene activation 61. The 
major oncogene Ras, when mutated, can induce glycolysis, as well as the mammalian 
target of rapamycin complex I (mTORC1). Akt kinase activation by 
phosphatidylinositol-3-OH kinase (PI3K) results in increased glucose uptake, 
hexokinase targeting to mitochondria and glycolytic flux 69, while the transcription 
factor myc has been shown to increase glutaminolysis and also to promote the 
alternative splicing of the pyruvate kinase gene PKM, resulting in the overexpression 
of PKM2 embryonic isoform 70. 
Similary to oncogenes, cell metabolism is also be influenced by tumour 
suppressor genes. Loss of the p53 protein prevents expression of the SCO2 gene 
(synthesis of cytochrome c oxidase) decreasing mitochondrial respiration 71. Also 
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TIGAR (TP-53-induced glycolysis and apoptosis regulator) inhibits glycolysis by 
increasing the expression of fructose-2,6-bisphosphate and the availability of glucose-
6-phosphate (G6P) to entry the pentose phosphate pathway (PPP) 72. 
Initially thought as a metabolic waste, lactate the end product of glycolysis, 
can be a paracrine signalling molecule 61.  Acidosis often precedes angiogenesis and it 
has been shown that lactate can stimulate HIF expression independently of hypoxia 73. 
Thus, instead of one event causing the Warburg effect, numerous factors play a role in 
determining the fate of glucose in cancer cells. HIF and other signalling pathways 
control glycolysis flux, which ends with the production of pyruvate. At the center of 
pyruvate metabolism lies the pyruvate dehydrogenase (PDH) complex, a multisubunit 
complex that catalyses the oxidative decarboxylation of pyruvate to Acetylcoenzyme 
A (ACoA) and conversion of NAD+ to NADH in the mitochondria. This complex is 
regulated by PDKs and phosphatases that control phosphorylation of the E1a subunit 
of the PDH complex to control its activity. Besides hypoxia, these kinases are also 
controlled by nutrient levels 65. Apart from phosphorylation, PDH complex activity is 
influenced by the mitochondrial NAD+/NADH ratio and ACoA levels. The complex 
regulation of PDH activity illustrates how diverse metabolic inputs can affect 
pyruvate fate. Importantly, this relationship between pyruvate/lactate and 
NAD+/NADH will only cooperate if the reaction is at equilibrium. The specific 
isoform of pyruvate kinase can also influence pyruvate to lactate conversion in cells 
74. The PKM2 isoform promotes anabolic metabolism with conversion of glucose into 
lactate, while high pyruvate kinase activity from the PKM1 isoform promotes 
efficient pyruvate oxidation in the TCA cycle 75.  
Another enzyme playing a critical role in the fate of pyruvate is LDH that 
catalyzes the interconversion of pyruvate and lactate with concomitant 
interconversion of NADH and NAD+. LDH-A is responsible for the rapid conversion 
of pyruvate into lactate with regeneration of NAD+, supporting the high glycolytic 
rates of cancer cells, while the isoform B converts lactate into pyruvate to undergo the 
TCA cycle (Figure 6).  
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Upregulation of glycolysis requires additional adaptations to overcome the 
negative effects of extracellular acidosis through resistance to apoptosis or 
upregulation of membrane transporters to maintain normal intracellular pH (pHi) 76. 
Thus, pHi is maintained by multiple families of H+ transporters that cooperate to 
protect the cytosol from acidification, such as Na+ /H+ exchanger (NHE) 77 and its 
isoforms, the vacuolar-type H+-ATPases (V-ATPase)78, the monocarboxylate 
transporters (MCTs) 79 and HCO3- transporters and exchangers (NBCs and AEs) 80,81. 
Several of these transporters have been shown to be upregulated in cancer.  Moreover, 
in hypoxic cancer cells, HIF-1α upregulates pHi-regulating systems such as MCT4 82 
and the membrane-associated carbonic anhydrases (CA) 83 CAIX and CAXII, that 
catalyse the extracellular hydration of CO2 into HCO3- and H+. Then, HCO3- enters 
the cell through AE1 where, in combination with the accumulating H+ derived from 
Figure 6: - Metabolic pathways active controlled by signaling pathways involving known oncogenes and tumor 
suppressor genes 1. Tumor suppressors are shown in red, and oncogenes are in green. Key metabolic pathways 
are labeled in purple with white boxes, and the enzymes controlling critical steps in these pathways are shown 
in blue. Some of these enzymes are candidates as novel therapeutic targets in cancer. Malic enzyme refers to 
NADP+-specific malate dehydrogenase [systematic name (S)-malate:NADP+ oxidoreductase (oxaloacetate-
decarboxylating)]. 
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the glycolytic metabolism, forms CO2 and H2O, that will exit the cell by diffusion, 
causing trapping of the H+ in the extracellular milieu (Figure 7) 84.  
 
 
No single event can explain a metabolic phenotype such as the Warburg 
effect. It is mandatory a tight regulation and sensing mechanism that allow cells to 
switch their metabolic phenotype to meet their energy demands. In addition to 
glucose, also glutamine is an energetic fuel 85. Furthermore, metabolites that 
participate in the glycerol-phosphate and malate-aspartate shuttle systems responsible 
for moving reducing equivalents across the mitochondrial membranes are also 
required for biosynthesis. Glycerol-3-phosphate is a side product of glycolysis and is 
involved in lipid synthesis, while aspartate is used to synthesize proteins and 
nucleotides. Most cells rely on lipids and some cancer cells have the ability to store 
triacylglycerides in lipid droplets that can be used as energy source 86.  
Figure 7: Uptake of glycolysis and pHi regulators. With high production of lactate and consequent acidification 
cells maintain a optimal intracellular pH expressing pH regulating systems as: Na+/H+ exchanger 1 (NHE1), 
Carbonic anhidrases (CA), Na+- dependent HCO3- transporter (NBC) Monocarboxylate transporters (MCTs) 
bicarbonate transporter exchanger (AE) and the H+ pump (V-ATPase) 76.  
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In opposition to what Warburg and followers postulated, that enhanced 
glycolysis is due to mitochondrial dysfunction, the fact is that most cancer cells 
maintain functional mitochondria 70.  
Mitochondria are essential for the production of cytoplasmic CoA, by citrate 
synthesis in TCA cycle, an important source of acetyl groups for protein acetylation 
and lipid synthesis 69,87. They can also be required to restore the NAD+ pool to 
support the high glycolytic fluxes 70. Besides this fact, it is true and becoming more 
obvious that being a tumour a group of heterogeneous cells it is possible to observe a 
whole scale of bioenergetics types. On one hand, cells adopt the glycolytic phenotype 
during the highest proliferative phase and in response to hypoxic conditions and, on 
the other hand, where glucose is limited, cells use OHPHOS to derive energy from 
glutaminolysis. There is another hypothesis proposed by Sonveaux and his co-
workers 88 for explaining the importance of these “different bioenergetic areas”. They 
described the existence of a hypoxic tumour cell compartment that relies on a 
metabolic symbiosis in which glycolytic/hypoxic and oxidative/oxygenated tumour 
cells mutually regulate their access to energy metabolites. They describe that lactate is 
an important metabolic fuel for oxygenated tumour cells. Thus, even in presence of 
glucose, cells import large amounts of lactate that is used to fuel the TCA cycle for 
ATP production. This symbiosis involves lactate recycling: oxidative tumour cells 
prefer to use lactate in the presence of glucose as an oxidative fuel, allowing glucose 
to diffuse farther from blood vessels where it is taken up by glycolytic tumour cells, 
in turn producing lactate in large quantities 89. However, this hypothesis is not yet 
completely proven and appears not to be observed in all tumours.  
 
 
1.3 Monocarboxylate transporters 
 
1.3.1 Characterization 
Lactic acid transport across the plasma membrane is fundamental for 
metabolism and pH regulation of all cells, by removing the lactic acid produced by 
glycolysis and allowing uptake by those cells that utilize it as a respiratory fuel, as 
does the heart cells 90. If lactic acid efflux does not occur, the increased intracellular 
concentration will lead to a decrease in pH inside the cell, leading to inhibition of 
glycolysis 91. Although it is lactic acid that is both produced and utilized by 
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metabolism, the pK of lactic acid is 3.86, which ensures that it dissociates almost 
entirely to the lactate anion at physiological pH. This charged species cannot cross the 
plasma membrane readily by free diffusion, but requires a specific transport 
mechanism, provided by MCTs 79,90. 
Monocarboxylate transporters or MCTs, constitute a family of proton-linked 
plasma membrane transporters that transport molecules (monocarboxylates), such as 
lactate, across biological membranes 92. 
 
 
Although lactate is the monocarboxylate which transport through the plasma 
membrane takes place in highest quantities, MCTs are also essential for the transport 
of other metabolically important monocarboxylates such as pyruvate and ketone 
bodies. Being so, MCTs play a central role in mammalian metabolism and are critical 
for the metabolic communication between cells (Figure 8) 79. 
The family of MCTs comprises 14 members already identified, each one with 
Figure 8: Pathways that involve the transport of monocarboxylates across the mitochondrial and plasma 
membranes 79. Glc-1-P and Glc-6-P, glucose 1-phosphate and glucose 6-phosphate; Ac+bHB, acetoacetate 
plus b-hydroxybutyrate. 
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properties connected with the metabolic requests of the tissues in which they are 
expressed. It is described that the topology of MCTs consists of 12 transmembrane α-
helical (TM) domains with the N- and C-termini located within the cytoplasm and a 
large cytosolic loop between TM6 and 7, as illustrated in Figure 9 79,93,94.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental evidence 95 indicates that none of the MCT family members is 
glycosylated. The first four isoforms are the best characterized. MCT1-4 catalyse the 
proton-coupled transport of monocarboxylates, playing an important role in cell 
metabolism. Other isoforms such as MCT6 were shown to transport synthetic drugs 
such as probenecid, bumetanide and the anti-diabetic drug Nateglinide 96, while 
MCT8 transports thyroid hormones 97,98. MCT10, besides the transport of thyroid 
hormones 97,99, has been identified as a transporter of aromatic amino acids 100. MCT9 
was recently described to transport carnitine 101. Recently MCT12 has been identified 
as a new creatinine tranporter 102. However, the function of the other members is still 
unknown (Table 1) 103. 
Since MCT1-4 isoforms are the ones which catalyse the proton coupled 
transport of monocarboxylates 100,104–107, they will be the ones to be boarded along 
this work. 
The mechanism that predicts that transport of lactate into the cell has been 
already identified 108. The transporter has a substrate-binding site open to the 
extracellular matrix, which firstly binds a proton, followed by the lactate anion 109. 
Figure 9: Membrane topology of the MCT family. The sequence shown is of MCT179. 
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The protein stucture change to a new conformation where both the proton and lactate 
(lactate first and then the proton) are exposed and released to the opposite surface of 
the membrane. 
 
Table 1: Members of the monocarboxylate transporter (MCT) family 103 (adapted from Halestrap et al 
2013)  
 
Moreover, Wilson and his co-workers described that the feature that is 
responsible for transport, is a lysine residue (Lys38) in TM1 that has only been 
C:	  Cotransport	  E:	  Exchanger	  F:	  Facilitated	  transporter	  O:	  Orphan	  transporter.	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recently identified in the MCT1 from rat 110. In this study the authors show that Lys38 
is normally uncharged in the hydrophobic environment of the ion pore, however, can 
bind to an extracellular H+ leading to the open conformation, and subsequently binds 
the lactate ion. Upon binding, both the H+ and lactate ions are transferred to an 
aspartate–arginine ion pair at TM8 (Asp302–Arg306) 111. A phenylalanine residue 
(Phe360) in TM10 that regulates the substrate selectivity of MCT1 was also identified 
112. However, in MCT3 and 4 instead of a Phe residue, a tyrosine residue is found in 
this position 95. This switch can explain the differences in lactate affinities between 
the four isoforms, which correlates with their function when expressed in a specific 
cell types. 79,92,95,103. Recently, a report showed that a arginine residue (Arg-278) in 
TMD8 is involved in substrate, L-lactate recognition by human MCT4 113. 
 
 
1.3.1.1 MCT1 
MCT1 was the first MCT isoform identified after being cloned from Chinese 
hamster ovary cells and later functionally expressed in a breast tumour cell line. 
Similar transporters from human, rat and mouse have been cloned and sequenced. 
This isoform is encoded by the gene slc16a1 and it has been mapped and located in 
the chromosomal band 1p13.2-p12 and it is found in the majority of tissues examined 
being the most well-studied and functionally characterized member of the MCT 
family. SLC16A1 comprises 5 coding exons with no evidence for splice variants 
within the coding region 79, however, 8 transcripts have been identified, 5 resulting in 
proteins of different sizes and 2 with no protein product (ENSG00000155380). The 
functional protein is composed by 500 amino acids and has a molecular weight of 
53,944 Daltons (P53985). This is the isoform with the widest tissue distribution 92.  
Different studies showed that MCT1 transport demonstrates Michaelis Menten 
kinetics with a broad specificity for short-chain monocarboxylates including those 
substituted on the 2 and 3 positions with with small groups such as hydroxyl, and 
carbonyl groups 104,114. The transport of short-chain fatty acids, such as acetate, 
propionate, and butyrate, is also facilitated by MCT1 115 however, these substrates can 
also enter cells by free diffusion in the undissociated form of the acid 93. Natural 
substrates for MCT1 include L-lactate, pyruvate, b-hydroxybutyrate, and acetoacetate 
and Km values for each one can vary (Table 2). To note that the transport of lactate is 
relatively stereoselective, with D-lactate being a poor substrate compared to L-lactate, 
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whereas such stereoselectivity is not demonstrated for 2-chloropropionate or b-
hydroxybutyrate. Besides all these substrates, the main function of MCT1 is to 
transport lactate coupled with a proton across plasma membrane. This transport can 
be bidirectional depending on the pH gradient between the intracellular and 
extracellular space 39,116.  
 
Table 2: Km values for the various substract between the diferent MCTs isoforms. 103 
 
 
1.3.1.2 MCT2    
The second isoform of MCT was sequenced and cloned 112 from Syrian 
hamster liver, a tissue where MCT1 is absent. Named MCT2, it shares 60% identity 
with MCT1 79,117. MCT2 is encoded by the gene slc16a7 and it is located in the locus 
12q14.1. It comprises 5 coding exons, and has 17 transcripts identified in a public 
database (ENSG00000118596) however only 8 result in protein. The functional 
protein is composed by 478 amino acids and has a molecular weight of 52,200 
Daltons (O60669). There are studies showing alternative splicing in both human and 
rat 118. This isoform has a higher affinity for monocarboxylates, increasing the affinity 
for the substrate relative to MCT1. Km values for pyruvate and L-lactate were found 
to be about 0.1 and 0.74 mM, respectively, compared to values of about 1 and 3.5 mM 
for MCT1 (Table 2).  Both Northern blot analysis and examination of the human 
expressed sequence tag (EST) database suggest that MCT2 has a lower expression in 
human tissues. This isoform is mainly present in cells where a rapid uptake of 
monocarboxylates is necessary, where these are in low concentrations and in cells 
which release of lactate is rare. Thus, it is expressed in proximal kidney tubules, 
neurons, sperm tails, cardiac myocytes and liver 39,112. MCT2 has a special important 
function in the brain where its expression is largely confined to the postsynaptic 
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density of the neurons and may facilitate the uptake of lactate for oxidation as a 
respiratory fuel 119,120 
 
 
1.3.1.3 MCT3 
MCT3 was first identified in the retinal epithelium cells of chicken 121. The 
functional protein is composed by 504 amino acids and has a molecular weight of 
52,319 Daltons (O95907). It is encoded by the gene slc16a8 and it is located in the 
locus 22q13.1. It seems to be a very specialized MCT since its expression is restricted 
to the basal membrane of the retinal pigment epithelium (RPE) of the eye and on the 
Choroid Plexus epithelium 122,123. It is thought to play an important role in facilitating 
the transport of glycolytically derived lactic acid out of the retina 93.   
 
 
1.3.1.4 MCT4 
Searching for novel members of MCT family in the EST database, Price and 
his co-workers identified MCT4 116. Initially called MCT3 based on its sequence 
homology with chick MCT3, it was renamed MCT4 after MCT3 had been identified. 
MCT4 is encoded by the gene slc16a3 and it is situated in the locus 17q25.3. Also 
with 5 coding exons, MCT4 has already 20 transcripts identified 
(ENSG00000141526). The protein is constituted by 465 residues and a molecular 
weight of 49,469 Daltons (O15427). It is a transporter of low affinity adapted for the 
export of lactate of glycolytic cells like muscle cells, tumour cells and white cells 124. 
It is expressed in chondrocytes, leucocytes, testicle, lung and in placenta where a 
quick transport of lactate is necessary from the fetus to the motherly circulation. 
MCT4 exhibits a lower affinity for most substrates and inhibitors than MCT1, with 
Km and Ki values some 5–10-fold higher 104,105. The high Km for pyruvate may be 
especially significant as this avoids loss of pyruvate from the cell, which prevents 
removal of the reduced form of NADH produced in glycolysis 93.  
  
 
1.3.4 MCTs: physiology and function 
As already described above, the transport across the plasma membrane by 
MCTs is of extreme importance for metabolic function. For many years lactate was 
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considered nothing more than a waste product of glycolysis. The accumulation of 
lactate within cells and their microenvironment, such as in muscle fibbers during 
exercise, was thought to cause lactic acidosis and consequences to normal 
physiological function 95. However, new discoveries during the last decades showed 
that lactate can be utilized as a metabolic substract for OXPHOS 89,125. This important 
role of lactate brought a huge impact on studying the role of MCT1-4 in the 
metabolism of the muscle, brain, kidney, liver and retina. Thus, the uptake of lactate 
is of great importance in liver and kidney, where lactic acid is transported into the cell 
to support gluconeogenesis and lipogenesis, and in heart, skeletal muscle and brain, 
where lactate, together with ketone bodies, is used as a major respiratory fuel 79. Both 
skeletal muscle and heart express MCT1 to meet this role, while in liver, kidney and 
brain both MCT isoforms 1 and 2 are expressed, with MCT2 with a higher affinity for 
lactate uptake 95. Lactic acid formation and its subsequent distribution throughout the 
body is of major importance, being responsible for the coordination of intermediary 
metabolism in different tissues, and cells within those tissues. This role of lactate as 
oxidative and gluconeogenic substrate, as well as in cell signalling, is explained by 
the “cell-cell” and “intracellular lactate shuttle” concepts 89,95,125126. This concept was 
introduced by Brooks in 1985 127, and according to this hypothesis, lactate produced 
in glycolytic cells will be utilised continuously under fully aerobic conditions. This 
lactate shuttle is identified between glycolytic muscle fibbers and oxidative muscle 
fibbers 127,128, between glycolytic astrocytes and oxidative neurons 95,129 and between 
tissues of net release of lactate and gluconeogenic tissues. As mentioned before, the 
differential expression of MCT isoforms correlates with their roles within different 
cell types where they facilitate lactate transport in the direction that can be predicted 
by the metabolic profile of the cells. In the retina, there is a similar interplay between 
different cell types with the photoreceptor cells and other neurons oxidising lactate 
exported from glial cells (Müller cells). In addition, lactate must be transported across 
the retinal pigment epithelium (RPE) to avoid accumulation of lactate within the 
subretinal space that could lead to osmotic swelling and detachment of the retina from 
the RPE. MCT1 is located on the apical surface of the RPE and transports lactate and 
water from the sub-retinal space into the RPE from where MCT3, located on the 
basolateral surface transports the lactate and osmotically obliged water into the 
choroidal blood supply 95. Two cell-cell lactate shuttles, in the brain and skeletal 
muscle, are described below with more detail (Figure 11).  
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ü Skeletal muscle lactate shuttle  
 
The best-established lactate shuttle is described in skeletal muscle. During 
intense exercise, fast-twitching glycolytic muscle fibbers (white muscle) become 
hypoxic and produce lactic acid, which is then released to the extracellular 
compartment. Then, this lactate can be taken up by slow-twitching muscle fibbers 
(red muscle) where it is utilized as a respiratory fuel, or shuttled into the blood stream 
for clearance in the kidney. Thus, for lactate transport, muscles express MCT1 and 
MCT4 with an isoform-specific pattern: tissues like heart and oxidative red muscle 
show higher expression of MCT1, for the uptake of lactic acid, whereas MCT4 
expression is seen largely in glycolytic white muscles 103,128.  
 
ü Brain lactate shuttle 
 
A fundamental principle in the physiology of brain energy metabolism is that 
neuronal activity is tightly coupled to blood flow and energy metabolism. Studies 
have shown that the brain tissue consumes lactate from blood 130. A similar lactate 
shuttle is proposed between astrocytes and neurons in the brain 125. MCT1 expression 
is found in astrocytes 131–133, as well as in brain endothelial cells 134,135 while MCT2 is 
exclusively found in neurons 131–133. MCT4 presents a strong expression in the plasma 
membrane of astrocytes. Thus, a mechanism of cell-cell lactate shuttle between 
astrocytes and neurons is described, where astrocytes perform aerobic glycolysis, 
exporting a substantial amount of lactate through MCT1 and MCT4 into the 
extracellular space that is then taken up by the neighbouring neurons through the high 
affinity lactate transporter MCT2 expressed on the cell surface (Figure 10) 129,136. 
Moreover, MCT activity is not limited to plasma membrane as neurons contain a 
mitochondrial lactate oxidation complex that has the potential to facilitate both 
intracellular and cell-cell lactate shuttles in brain 137. 
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1.3.4.1 MCTs as drug carriers 
 
In addition to their roles in metabolism, MCTs may also act as drug 
transporters 138. Few studies have been conducted assessing the contribution of MCT 
isoforms to overall drug disposition and the impact of MCT modulation on drug 
pharmacokinetics and disposition 138. Thus, MCTs isoforms have been reported to 
mediate the transport of gamma-hydroxybutyrate (GHB) 139,140 a neuromodulator that 
binds to the GABA(B) receptor and is therapeutical use in in narcolepsy and alcohol 
withdrawal 141, however, abuse of GHB is widespread. Furthermore, MCTs are also 
involved in the transport of other drugs as salicylic acid 142, pravastatin 143 and 
atorvastatin 144, among others. Importantly, MCT1 was found to be the main 
determinant of 3-bromopyruvate (3-BrPA) uptake and sensitivity and also to be 
necessary for the uptake in cancer cells 145. Further investigations are required to more 
clearly understand the role of MCTs in drug disposition for a wider range of drug 
substrates. 
 
 
Figure 10: The role of different MCT isoforms in shuttling lactate between producing and 
utilizing cells in the muscle and brain 103.  
 
General Introduction 
	   25	  
 
1.3.3 Regulation of MCTs 
 
Importantly, MCT regulatory mechanisms vary among isoforms, which allow 
induction of expression of specific isoforms upon different stimuli, adapting cells to 
different energy demands. MCTs carry multiple splice variants and differ only at the 
5′-UTR regions, suggesting that they have transcripts that can be subject to both 
transcriptional and post-transcriptional regulation 95. This level of control may be 
necessary because MCT1 and MCT4 are widely expressed in many different cell 
types, thus requiring additional mechanisms to regulate their relative abundance in a 
cell-specific manner 146.  
Expression studies showed that c-Myc amplification appeared to be coupled 
with the modulation of SLC16A1 expression 147,148 and the pro-inflammatory 
cytokines IFN-γ and TNF-α, have also been implicated in the transcriptional control 
of MCT1, by down-regulating SLC16A1 transcription 149,150.  Another tumour 
suppressor gene that has been shown to regulate MCT expression is p53. Evidence 
shows that under hypoxic conditions, loss of p53 promotes MCT1 expression. p53 
interacts directly with the MCT1 gene promoter and alters MCT1 mRNA stabilization 
151. The latter study also showed that in hypoxic conditions in p53 -/- tumor cells, NF-
κB further supported expression of MCT1. The regulation of MCTs via NF-κB was 
also demonstrated by another group in human colonic Caco-2 cells. 152 
Hypoxia conditions, which are known to induce the glycolytic phenotype, are 
also associated with altered expression of MCTs. Several studies suggest that hypoxia 
regulates MCT1, MCT2 and MCT4 153–155, however only Ullah et al demonstrated 
that the activity of the MCT4 promoter (but not that of MCT1 or MCT2) is stimulated 
by hypoxia and is mediated by HIF-1a binding to two hypoxia response elements 
(HRE) in the MCT4 promoter 82. The overexpression in MCT4 expression in response 
to hypoxia is observed in several tissues and cell lines and is consistent with the role 
of MCT4 in mediating lactic acid production from glycolytic tissues 156. 
During heavy exercise, the rapid increase in the energy demand of contracting 
skeletal muscles is associated with an increase in glycolysis and subsequent 
production and accumulation of lactate and protons 91. Thus, evidence demonstrates 
that acute exercise alters human MCT expression 157–160, producing a greater increase 
in MCT1 than MCT4 content within the first 24h from the onset of exercise128. 
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Recently, experiments showed that the overexpression of MCT1 and MCT4 mRNA 
after acute exercise may be mediated by AMPK activation 161.  
Furthermore, carbonic anhydrase (CA) has been shown to facilitate 
lactate/proton exchange in rat skeletal muscle 162, and when MCT1 and CA are co-
expressed in oocytes, they cooperate with binding of CA to MCT1, increasing the flux 
of protons via MCT1 163,164, however, this effect is independent of the catalytic 
activity of CA. Similar results have recently been observed between MCT4 and CA 
165. In humans, inhibition of extracellular and intracellular CA activity has been 
demonstrated to be associated with a lower plasma lactate concentration during 
incremental exercise 166, which may due to lower activity of MCT.  Thus, the activity 
of both MCT1 and MCT4 is enhanced by interaction with intracellular CAII, whilst 
that of MCT2 is stimulated by interaction with extracellular CAIV. MCTs can also 
interact functionally with sodium bicarbonate co-transporter (NBCs) in a cooperative 
mechanism to regulate pH, enhancing the activity of both MCT1 and NBC 167167. 
MCTs 1–4 carry out their physiological function by mediating lactate 
transport, but they are just as capable of transporting other substrates, which can 
regulate their expression.  Evidence has demonstrated substrate-induced upregulation 
of MCT expression and function via transcriptional mechanisms 168. Moreover, 
exposure to butyrate resulted in a concentration- and time- dependent increase in 
MCT1 mRNA and protein expression, with a corresponding increase in butyrate 
transport 115. Moreover, butyrate activates the monocarboxylate transporter MCT4 
expression in breast cancer cells 169. 
Furthermore, MCT1 transcripts can also be regulated by microRNAs, which 
target the mRNA at its 3’-UTR for translational repression or mRNA degradation 170. 
This mechanism is particularly important in pancreatic β-cells, where MCT1 is not 
normally expressed. Studies show that promoter-activating mutations MCT1 
expression in β-cells allow pyruvate uptake and pyruvate-stimulated insulin release, 
despite inducing hypoglycaemia 171. Thus, MCT1 expression is silenced in pancreatic 
cells at least in part by miRNAs selectively present in this cell type. 
Many membrane proteins are tightly associated with other glycosylated 
membrane proteins 172.  Kirk and his co-workers when trying to overexpress both 
MCT1 and MCT4 in a cell line, realized that the proteins accumulated in the 
perinuclear region, characteristic of the Golgi apparatus instead of being translocated 
to the plasma membrane 173. However, when co-expressed with a cell surface 
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glycoprotein CD147/basigin, both MCT1 and MCT4 were correctly targeted to the 
plasma membrane, suggesting that MCTs rely on this chaperone for their correct 
location 173,174. CD147/basigin, also known as EMMPRIN, is widely distributed and 
expressed in high levels in many tissues, mainly in metabolically active cells such as 
lymphoblasts and malignant tumour cells. Elevated CD147 stimulates matrix 
metalloproteinase (MMP)-production in stromal fibroblasts and endothelial cells, 
leading to extracellular matrix degradation, tumour growth promotion, and metastasis. 
CD147 also stimulates expression of VEGF 175.  
Thus, acting as an essential chaperone, CD147 leads the correct activity and 
targeting of at least MCT1 and 4 to the plasma membrane 176. MCT2 interacts 
preferentially with another ancillary protein called embigin (gp70), which is a CD147 
homologue with an unreactive Ig-like V domain in place of the C2 domain 174. Other 
basigin family members may bind different ligands through the extracellular Ig-like 
domains, which are less similar than the transmembrane and cytoplasmatic regions 
172. GP70, that shares the ability of CD147 to also interact with MCT1, is strongly and 
broadly expressed during the early stages of embryogenesis, but has a much more 
restricted distribution in adults 110,173. (See a more complete review on the role of 
CD147 in lactate transporter in tumour cells in Chapter 3)  
 
1.3.4 MCT Inhibition 
 
There are numerous non-physiological competitive inhibitors described that 
are known to inhibit the function of MCTs 177. Several studies have demonstrated the 
affinity and specificity of each inhibitor to each MCT isoform. These include 
aromatic compounds such as α-cyano-4-hydroxycinnamate (CHC) and 
phenylpyruvate (ki value of 50- 500 µM), stilbene disulfonates such as 4,4’-di-
isothiocyanostilbene-2,2’-disulfonate (DIDS) and 4,4’-dibenzamidostilbene-2,2’-
disulfonate (DBDS). These inhibitors inhibit MCTs with higher affinity for MCT1 
and 2, although they have the ability to also inhibit other transporters. CHC has been 
shown to be a potent inhibitor of the mitochondrial pyruvate transporter, whereas 
DIDS and DBDS inhibit the chloride/bicarbonate exchanger AE1 110,178. 
Bioflavonoids such as phloretin and quercetin and thiol reagents as p-
chloromercuribenzenesulfonic acid (p-CMBS) are also non-specific MCT inhibitors 
93,177. MCT2 is not inhibited by p-CMBS because this compound inhibits MCTs by 
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targeting the chaperone CD147 and not GP70 174. For MCT4, a smaller inhibition by 
DIDS or CHC is observed due to the lower affinity for this drug when compared to 
MCT1 93. A new class of specific and high-affinity inhibitors of MCT1/2 have 
recently been developed by AstraZeneca. The authors found it to be active against 
MCT1 and MCT2 but not MCT4. AR-C155858 inhibitor seems to exert its function 
by binding MCT1 from the cytosolic side. The use of chimeric transporters combining 
different domains of MCT1 and MCT4 revealed that the binding site for the inhibitor 
is contained within the C-terminal of MCT1, and involves TM 7–10 179. 
 
1.3.5 Monocarboxylate transporters: embryo vs cancer 
 
The importance of members of the SLC16 family, and especially the proton-
linked monocarboxylate transporters MCT1-4, is clear in a wide range of 
physiological and pathological process and additional roles will probably be 
discovered.   
Since the role of MCTs in embryo and cancer is the main subject of this thesis, 
a more detailed review of the state of the art is described in chapter 2 and 3, 
respectively. 
 
  1.3.6 Is inhibition of MCTs a promising strategy to improve the efficacy 
of cancer therapy? 
  
 It is described that the metabolic properties of cancer cells are different from those 
of normal cells. Metabolic reprogramming renders cancer cells  dependent on specific 
metabolic enzymes or pathways that could be exploited for cancer therapy (Figure 
12). However, the search for suitable targets may be complicated by the high 
plasticity of the metabolic network that can induce compensatory biosynthetic routes 
70. The development of treatments that target tumour metabolism is receiving renewed 
attention, with several potential drugs targeting metabolic pathways, already in 
clinical trials (Table 3, for review see 4). Regarding MCTs, after the development of 
specific inhibitors for MCT1/2 by AstraZeneca, the compound AZD3965 is already 
being tested in a phase 1clinical trial in patients with advanced solid tumours (prostate 
and gastric) or lymphomas 180. 
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The inhibition of glycolysis seems to be tolerated remarkably well by normal 
tissues, but could have a disappointingly limited effect on tumourigenesis as 
monotherapy 4,181. Cancer cells are characterized by their plasticity, being able to 
reprogramme their energetic metabolism, switching to other bioenergetic pathways to 
survive. Actually, there is already evidence showing that anti-glycolysis treatment 
could lead to increased glutaminolysis or oxidative phosphorylation to produce 
energy 182. Thus, new strategies should be adopted and better and specific tumour cell 
therapies and treatment regimens need to be designed. 
Figure	  11:	  Actual	   therapeutic	   targets	  of	   tumour	  cell	  metabolism	  reported.	  Key	  enzymes	  are	  shown	   in	  green	  
boxes	  and	  key	  biosynthetic	  endpoints	  listed	  in	  purple	  1.	  GLUT	  –	  Glucose	  transporter;	  HK2	  –	  Hexokinase-­‐2;	  PFK1	  
–	   Phosphofructokinase	   1;	   PFKFB3	   –	   6-­‐phosphofructo-­‐2-­‐	   kinase/fructose-­‐2,6-­‐	   biphosphatase	   3;	   PK-­‐M2	   –	  
pyruvate	  kinase-­‐M2;	  LDHA	  –	  lactate	  dehydrogenase-­‐A;	  MCT1/4	  –	  Monocarboxylate	  transporters	  1/4;	  AMPK	  –	  
AMP	   activated	   protein	   kinase;	   G6PD	   –	   glucose-­‐6-­‐phosphate	   dehydrogenase;TKT	   –	   transketolase;TKTL1	   –	  
transketolase	  like	  -­‐1;	  ASCT2	  –	  solute	  carrier	  family	  1,	  member	  5	  [SLC1A5];	  GLS1	  –	  Glutaminase	  1;	  ME	  –	  malic	  
enzyme;	  FH	  –	   fumarate	  hydratase;	  SDH	  –	  succinate	  dehydrogenase;	  PDH	  –	  pyruvate	  dehydrogenase;	  PDK1	  –	  
pyruvate	  dehydrogenase	   kinase	  1;	  ACLY	  –	  ATP	   citrate	   lyase;	  ACACA	  –	  acetyl-­‐CoA	   carboxylase	  alpha;	   FASN	  –	  
fatty	  acid	  synthase;	  CA9/12	  –	  carbonic	  anhydrase	  9/12;	  NHE1-­‐	  Na+-­‐H+	  exchanger	  [SLC9A1]	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Table 3: Compounds targeting tumour metabolism currently in clinical studies. (adapted from Tennant 
et al 20104) 
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RATIONALE 
 
The human embryo develops in a hypoxic environment. In this way, cells have 
to rely on the glycolytic pathway for energy supply, leading to an intracellular 
accumulation of monocarboxylates such as lactate and pyruvate 1. These acids have 
an important role in cell metabolism and their rapid transport across the plasma 
membrane is crucial for the maintenance of intracellular pH homeostasis 2–4. This 
transport is mediated by a family of transporters, designated by monocarboxylate 
transporters (MCTs), namely isoforms 1 and 4. MCT1/4 expression is regulated by 
the ancillary protein CD147 5. The general aim of this project was to characterize the 
expression pattern of MCT1/4, CD147 and the glucose transporter GLUT1 during 
human fetal lung development by immunohistochemistry and elucidate the role of 
MCTs in lung development by studying the effects of MCT inhibition in fetal lung 
viability and branching. Rat fetal lung explant cultures were exposed to different 
doses of CHC, an inhibitor of MCT activity. Our findings show all the biomarkers are 
differently expressed during fetal lung development and that CHC appears to have an 
inhibitory effect on lung branching and viability, in a dose dependent way. To 
conclude, it appears that MCTs play a role in embryo development, however to prove 
the dependence of MCT activity further studies will be needed. 
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2.2.1 INTRODUCTION 
 
2.2.1.1Developmental biology 
 
The process by which the embryo is formed and develops is known as 
embryogenesis. It is initiated by a process called fertilization that is the fusion of 
genetic material from the two gametes, the sperm and the egg. After that cleavage 
begins which consist on a series of rapid mitotic divisions wherein the zygote is 
divided into numerous smaller cells. These different cells derived from cleavage, up 
to the blastula stage, are called blastomeres. The blastula is usually a spherical layer 
of cells, the blastoderm, surrounding a fluid-filled or yolk-filled cavity, the blastocoel. 
The cells then migrate to the interior of the blastula, consequently forming three germ 
layers. During this process the embryo is called gastrula. The germ layers are referred 
to as the ectoderm, mesoderm and endoderm and give rise to all of an animal’s tissues 
and organs through the process of organogenesis 1.  
 
ü Lung Development 
 
The development of the lung appears on the day 14th
 
of gestation 1. The 
respiratory system arises from the ventral foregut endoderm. The lung buds consist of 
three cell layers: the inner epithelium (endodermal origin), which is surrounded by 
loosely packed mesenchyme and a thin outer mesothelial (squamous epithelial) layer. 
The bronchial tree develops by branching of the bronchial epithelium around the 
mesenchyme 2. The mesenchymal cells of the lung are not as well characterized as the 
epithelial cells. The initial lung buds are composed of endodermal epithelium 
surrounded by mesenchyme. Relatively little is known about the development, 
maintenance, and lineage relationships of the mesenchymal cell types in the distal 
lung. It is controversial the number of different differentiated mesenchymal cell types 
in the adult lung, or the molecular markers which can be used to distinguish between 
them 3.  These include the endothelium of veins, arteries, capillaries, and lymphatic 
vessels as well as pericytes, fibroblasts, vascular and airway smooth muscle, 
myofibroblasts, lipocytes, and mesothelium 4. 
The development of the lung can be divided into 5 stages: embryonic, 
pseudoglandular, canalicular, saccular and alveolar stage (Figure 1) 5.  
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During embryonic development the epithelium of the lung bud undergoes 
branching morphogenesis given rise to the structure of the bronchioles and alveoli. 
Initial branches are mostly side-branches, which form by budding along the length of 
the tube 2. The branching epithelium initially generates the future bronchioles 
(pseudoglandular stages of lung development). The distal epithelium continues to 
branch (canalicular stage), although budding morphology and frequency changes 
continuously occur giving rive to the future alveolar development, the terminal sacs. 
These sacs increase in number during saccular stage becoming during the alveolar 
phases mature alveoli and alveolar ducts. The alveolar epithelium consists of type 1 
and type 2 alveolar epithelial cells. The type 2 cells contain abundant secretory 
vesicles called lamellar bodies that will produce the components for the surfactant 
media 6. In contrast type 1 cells are flat or squamous and approximately 95% of the 
surface area of the lung even though they account only for a minor proportion of the 
total population 7. Their high membrane to cytoplasm ratio, and the proximity 
alveolar capillary network, and expression of ion channels and pores support the 
notions that type 1 cells are the primary sites of gas exchange and that they also 
regulate fluid homoeostasis 8. The lung vasculature forms, in part, by migration of 
blood vessels from the aortic arches and from the left atrium to the lung 
Figure 1: Overview of prenatal lung development: phases of the developing lung 5. 
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(angiogenesis). Blood vessels also develop by vasculogenesis in the lung 
mesenchyme near developing epithelial buds; a rudimentary capillary network 
initially forms and expands, and later connects to the larger vessels to give rise to the 
lung vasculature.  
 
 
ü MCTs in embryo development 
 
The ability to sense and respond to changes in oxygen concentration is a 
fundamental requirement for the survival of all organisms. 
Localized hypoxia is a normal feature of embryo development 9, and this low 
fetal oxygen environment is one of the most important extracellular factors for lung 
morphogenesis 10,11, which is a complex process 12,13. Given this idea that lung 
development occurs in a hypoxic environment, it is not surprising that HIFs would be 
important contributors to embryogenesis. Indeed, HIF mRNA and protein levels are 
quite high in the fetal lung 10,14, with the entire HIF system in place as early as 8 
weeks of gestation in the human 10. HIF- 1a protein expression is induced by hypoxia 
in cultured cells derived from all cell types found in the adult lung 15, whereas HIF-2a 
protein expression is restricted to the vascular endothelium and type II pneumocytes 
16. During fetal development, the lung of the normal embryo is hypoxic 11, and 
analysis of the spatial pattern of expression in human lungs during initial development 
of the pulmonary vasculature revealed high levels of HIF-1a protein localized 
predominantly in branching epithelium 17. HIF-2a protein was also present in 
epithelium, as well as in mesenchymal structures, which give rise to the vascular 
endothelium 17. Given the distinct expression pattern observed in the developing lung, 
HIF-1a and HIF-2a may serve different, and specific, functions in epithelial and 
vascular morphogenesis. In this context, HIF system plays a critical role in pulmonary 
development. While some studies suggest that low oxygen favours airway branching 
and bud formation 18,19 other suggest that the growth of buds occurs at higher oxygen 
consumption 20,21. Thus, the role of hypoxia during lung branching is not really 
elucidated. On the other hand vascular branching, by contrast, is almost completely 
dependent on the low oxygen tension of the fetal lung and it is abolished 
experimentally when the levels increase 10,21,22. These controversies in the fluctuant 
levels of oxygen during lung development it is also reflected on how do cell obtain 
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energy to grow and differentiate. Thus embryo cells may, at some stage, rely 
primarily on glycolytic metabolism for energy production 23,24, a necessary adaptation 
for the environmental hypoxia 25. 
Several studies have been already demonstrated the expression of MCTs 
during pre-implantation development of the human and mouse. The authors 26,27 
demonstrated that since the development of the zygote until the stage of 2 cells, there 
is an absolute requirement for pyruvate and that lactate could support the 
development of the embryo in stages of 4 and 8 cells. For that is required a system 
that is capable of transporting lactate, pyruvate and protons in order to counteract the 
decreasing of pH inside the cell. Thus, Hérubel et al 28 analyzed and compared the 
expression of MCT1, MCT2, MCT3, MCT4 and basigin during stages of the early 
embryonic development of the human and mouse. For both human and mouse the 
transcript of MCT1, MCT2 and basigin were detected during all stages studied. 
MCT3 was detected neither in human nor in mouse and MCT4 was detected during 
all stages but only for mouse. Also, Harding and co workers examined changes in the 
activity of the MCTs during early mouse embryo development and the relationship 
between MCTs and pHi 27. They demonstrated the presence of mRNA for MCT1, 
MCT2 and MCT3 isoforms throughout pre-implantation of the mouse. Furthermore, 
they studied MCT activity by inhibition with pCMBS and they suggested that MCT1 
is the predominant isoform on the regulation of the pHi during early development of 
the mouse.  Thus, MCTs have a crucial role during the preimplatation of the embryo 
during early embryonic development of human and mouse 26–29  
Regarding organogenesis there are also some studies reporting the expression 
of MCTs. MCT-4 isoform and basigin are co-expressed in the early differentiating 
cardiomyocytes in the developing heart of chick embryos 24 and MCT1 and MCT2 are 
expressed in the forebrain of rat embryos between embryonic day 16 and postnatal 
day 14.  
The role of MCTs in the lung development it is not elucidated. Troug and co-
workers 12 evaluated the effect of hypoxia on lung development. They observed that 
chronic hypoxia at the end of gestation interrupted lung development and they 
detected upregulation of MCT4 in these tissues. However, there are no studies 
demonstrating the expression of MCTs during the process of embryogenesis and 
specifically lung morphogenesis. In this work, we evaluate for the first time the 
expression of MCT1/4, CD147, the glucose transporter 1 (GLUT1) and the biomarker 
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of hypoxia carbonic anhydrase 9 (CAIX) in a human fetal lung series and evaluate the 
effect of MCT inhibition on viability and branching morphogenesis of rat fetal lungs.   
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2.2.2 MATERIAL AND METHODS 
 
2.2.2.1Human tissue specimens 
All the cases were retrieved from the laboratory of pathology from CGC 
genetics in Porto. Fetal human tissues were selected from late spontaneous abortions 
between 12th and 37th weeks of gestational age. Placental abruption occurred in all 
cases, including one case of fetal focal defects of the distal extremities in a context of 
amniotic bands, and other case with clinical features suggestive of chromosomal 
anomalies confirmed by cytogenetic studies (trisomy 21), which had a cardiac 
ventricular septal defect. None of the other fetus had developmental abnormalities. 
All cases had permission for autopsy and were donated for pathologic/scientific 
research. All tissues were collected after informed consent in accordance with the 
Ethics Guidelines of CGC clinics. 
 
2.2.2.2 Animal model  
Animal experiments were performed according to the Portuguese law for 
animal welfare. Animals were housed in an accredited rat house and treated as 
specified in the Guide for the Care and Use of Laboratory Animals published by the 
US National Institutes of Healths (National Institutes of Health Publication No.85-23, 
revised 1996). Sprague–Dawley female rats (Charles-River, Barcelona, Spain) were 
maintained in appropriate cages under controlled conditions, fed with commercial 
solid food. After mating, they were checked for intracoital plugging and all pregnant 
rats were sacrificed by decapitation. Fetal rat lung tissues were obtained from fetuses 
harvested by caesarean section at 15.5 (pseudoglandular phase), 17.5 (canalicular 
phase), 19.5 (saccular phase) and 21.5 (alveolar phase) day post-conception (dpc). 
Samples were fixed in formalin, embedded in paraffin and 4µm sections were used for 
immunohistochemistry (IHC). 
 
2.2.2.3 Immunohistochemistry 
IHC for MCT1 (1:200 dilution; AB3538P; Chemicon International) was 
performed according to the avidin-biotin-peroxidase principle (R.T.U. Vectastin Elite 
ABC kit; Vector Laboratories), as previously described by our group 30. MCT4 
(1:1000 dilution, H-90; sc-50329; Santa Cruz Biotechnology), GLUT1 (1:500 
dilution; ab15309; Abcam) and CAIX (1:1000 dilution; ab15086; Abcam) IHC was 
MCTs in lung development 
	   63	  
performed with the Ultravision Detection System Anti-polyvalent, HRP (Lab Vision 
Corporation), as previously described 30,31. CD147 (1:300 dilution; sc-71038; Santa 
Cruz Biotechnology diluted) IHC was performed using the UltraVision ONE 
Detection System: HRP Polymer (Lab Vision Corporation). In brief, paraffin 
embedded sections were deparaffinized in xylene and hydrated in a graded series of 
ethanol solutions. For antigen retrieval, slides were incubated with 1mM EDTA 
buffered solution (pH 8.0) for 20 min in water bath at 98°C. Slides were incubated 
overnight at room temperature with the primary antibody CD147. Tissues were 
stained with 3,3’-diamino-benzidine (DAB + Substrate System, DakoCytomation) for 
10 min and counterstained with haematoxylin. Colon carcinoma tissue was used as 
positive control for MCT1, MCT4, CD147 and GLUT1 and normal stomach tissue for 
CAIX. Stained slides were evaluated and then photographed under a bright field 
microscope. 
 
2.2.2.4 Rat fetal lung explant cultures  
Fetuses were removed by caesarean section at 13.5 dpc. Harvesting and 
dissection of the lungs was made in Dulbecco’s Phosphate Buffered Saline (DPBS - 
Lonza) under a dissection microscope (Leica MZFLIII, Wetzlar, Germany). Lungs 
were transferred to Nucleopore membranes with 8 mm pore size (Whatman, Clifton, 
NJ, USA) and incubated in a 24-well culture plates from Costar (Corning, NY, USA). 
Membranes were pre-soaked in DMEM (Lonza) for 1 hour before the explants were 
placed on them. Floating cultures of the explants were incubated in 200 ul of 50% 
Dulbecco’s modified eagle medium (DMEM), 50% nutrient mixture F-12 (Invitrogen, 
Carlsbad, CA, USA) supplemented with 100 mg/ ml streptomycin, 100 units/mL 
penicillin (Invitrogen), 0.25 mg/mL ascorbic acid (Sigma–Aldrich, St Louis, MO, 
USA) and 10% fetal calf serum (Invitrogen). After 1 hour incubation, 200 µl of 
medium with the inhibitor (CHC) at pH 7.4 was added. Fetal lung explants were 
incubated for 96 hours, at 37°C and 5% CO2. The medium with inhibitor was replaced 
every 24 h for 4 days. Fetal lungs were photographed daily and D0 was considered 
the first day and D4 the last. At the end of the incubation time, explants were washed 
in PBS and stored at -80°C until use. 
 
2.2.2.5 Morphometric analysis of lung explants  
Branching morphogenesis was monitored daily by photographing the 
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explants. At day 0 (D0: 0 h) and 4 (D4: 96h) of culture, the total number of peripheral 
airway buds (branching), the epithelial perimeter and total explant area in all lung 
explants were measured using a specific software developed by the laboratory 32. For 
all experimental conditions, results of branching and epithelial perimeter were 
expressed as D4/D0 ratio. 
 
2.2.2.6 Western blot 
Expression of MCT1 and MCT4 was also evaluated by Western blotting in 
rat embryo samples. Total protein was extracted from the lung explants at stages 16, 
18, 20 and 22. After maceration of the lungs with lysis buffer, the homogenate was 
centrifuged at 13000 rpm for 15 min at 4°C. The supernatants were collected and 
protein concentrations were determined by the DC Protein Assay Kit (500-0113, 
BioRad). 40 µg of protein of each sample were separated on 10% (w/v) 
polyacrylamide gels and transferred onto nitrocellulose membranes (Amersham 
Biosciences). After that, membranes were blocked with 0.1% Tween, 1% BSA in 
TBS for 1h and then incubated overnight at 4°C with the primary polyclonal 
antibodies for MCT1 (1:200 dilution; AB3538P; Chemicon International) and MCT4 
(1:1000 dilution, H-90; sc-50329; Santa Cruz Biotechnology). After washing with 
TBS-0.1%Tween, membranes were incubated with an anti-rabbit secondary antibody 
coupled to horseradish peroxidase (SantaCruz Biotechnology, 1/5000 in TBS-0.1% 
Tween, 1% BSA). At the end, bound antibodies were visualized by 
chemiluminescence (Supersignal West Femto kit; Pierce). For loading control, blots 
were probed with β-tubulin monoclonal antibody (1:200000 dilution, Abcam, UK). 
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2.2.3 RESULTS 
 
2.2.3.1 Expression of MCTs along human lung embryo development  
 
We evaluated the expression of MCT1, MCT4, CD147, CAIX and GLUT1 
in in human fetal lung samples (Figure 2). Lung tissue samples were collected and 
divided into 4 groups, according to the lung development phases: pseudoglandular 
(11-17 weeks of gestation; n=7); canalicular (18-25 weeks; n= 8); saccular (24-36 
weeks; n= 5) and alveolar (37-40 weeks; n=3). All proteins were expressed in the 
pseudoglandular phase of human lung gestation. MCT1 immunoreactivity was 
primarily detected in mesenchymal cells and in primitive epithelial alveolar cells. 
From 15 weeks of gestation, staining decreased in mesenchymal cells and started to 
appear also in the bronchial epithelium. In contrast, MCT4 and GLUT1 proteins were 
consistently early detected in bronchial and primitive alveolar epithelial cells and 
absent in mesenchymal cells. CD147 expression was only observed from week 16 in 
mesenchymal cells, primitive epithelial alveolar cells and on the bronchial epithelial 
cells, however staining was weak. At 17 weeks of gestation, CD147 was strongly 
detected in the basal region of the primitive epithelial alveolar cells and also on 
bronchial epithelium and mesenchymal cells. CAIX expression was restricted to the 
bronchial epithelial cells along this phase.  
During the canalicular phase, MCT1 expression continues to decrease in 
mesenchymal cells and to become more intense in the apical region of bronchial 
epithelium cells and in the basal region of alveolar cells. MCT4 and GLUT1 have 
similar expression patterns, maintaining the expression in the bronchial epithelial cells 
from 18 to 25 weeks of gestation and becoming absent in alveolar cells from week 19. 
MCT4 was focally detected in the glands of the bronchial epithelium. CD147 and 
CAIX expression varies during this phase. First, CD147 is only detected in the 
epithelium of the principal bronchus while CAIX is absent. From week 22, CD147 is 
expressed in mesenchymal cells, and both CD147 and CAIX are present in epithelial 
alveolar and bronchial cells.  
In saccular/alveolar phase, MCT1 expression decreased in the bronchial 
epithelium and is detected in pneumocytes type 2. 
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Figure 2: A - Immunohistochemical analysis of MCT1, MCT4, CD147, GLUT1 and CAIX during human fetal lung 
development. Immunoreaction was differently detected in mesenchymal cells (yellow arrow), primitive alveolar cells 
(purple arrow), bronchial epithelium (blue arrow) and alveolar type II cells (orange arrow). B- Illustrative scheme of 
the expression pattern of MCT1, MCT4, CD147, GLUT1 and CAIX during the lung embryo development phases. 
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MCT4 expression remained similar to canalicular phase while GLUT1 is absent. 
CD147 immunoreactivity is detected predominantly in the bronchi epithelium, being 
weak or even absent in the alveolar epithelium. CAIX expression is detected in both 
alveolar and bronchial epithelium.  
CD147, CAIX and MCT1 were also detected in the mesothelium. CAIX is 
mainly expressed in vessels during all stages of gestation  
 
 
2.2.3.2 Expression of MCTs in fetal rat lung  
 
Firstly we confirmed the expression of MCTs in rat fetal lung tissues. Thus, 
we performed IHC on samples corresponding to pseudoglandular (15.5 dpc), 
canalicular (17,5 dpc), saccular (19.5 dpc) and alveolar phase (21.5 dpc). By analysis 
of Figure 3A, it is possible to see that both isoforms are expressed in fetal lung 
throughout all studied gestational ages. MCT1 and MCT4 were predominantly 
expressed in the plasma membrane of bronchiolar and alveolar epithelial cells from 
all studied gestational stages, while immunoreaction in mesenchymal cells was 
observed for MCT1 at 17.5 dpc and 19.5dpc and for MCT4 at 15.5, 17.5 and 19.5 
dpc.  
Western blot analysis for MCT1 and MCT4 revealed bands around 50 kDa 
and 43 KDa, respectively, consistent with the molecular weight described for these 
proteins (Figure 3B). Thus, we confirm that both MCT1 and MCT4 are expressed 
throughout all gestational stages in rat fetal lung.  
 
 
2.2.3.3 Effect of MCT inhibition on rat lung morphogenesis 
 
We aimed to understand the contribution of MCTs to lung morphogenesis. 
For that we cultured rat fetal lung explants and MCT activity was inhibited with CHC, 
a classical MCT inhibitor.  
For this study, 30 lung explants were cultured with two doses of CHC (0.5 
mM and 1mM). Representative pictures of fetal lung explants are illustrated in figure 
4A. Comparing fetal lung explants treated with CHC at D4 with control (DMSO) it 
appears that CHC had an inhibitory effect in both doses studied (figure 4B). 
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Morphometric analyses showed that 1mM CHC had a significant inhibitory effect on 
branching morphogenesis (p<0.05). There was a decrease of the epithelial perimeter 
area and external perimeter of lung explants, in a dose dependent way, being 
significant for 1mM CHC (p<0.05).  
 
 
 
 
 
 
Figure 3: A – Expression pattern of MCT1 (left column) and MCT4 (right column) during rat fetal lung 
development. Both isoforms are expressed throughout all stages of lung development studied, from early 
15.5 dpc until late 21.5 dpc. Original magnification ×200. B – Western blot analysis of both MCT1 and 
MCT4 during the lung development phases: (1) 15.5 dpc; (2) 17.5 dcp; (3) 19.5 dpc; (4) 21.5 dpc. β-
tubulin was used as loading control. 
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Figure 4: A - Branching morphogenesis in rat lung explants treated with CHC (0.5mM and 1mM). 
The first line represent lung explants at D0, the second line represent lung explants treated with different doses of 
CHC at D4. (n=12 per condition); B - Morphometric analysis; i/ii: epithelial external and internal perimeter; iii: 
total number of peripheral airway buds; iv/v epithelial area. Numeric results are expressed as D4/D0 ratio. p<0.05; 
* vs control (DMSO). 
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2.2.4 DISCUSSION  
 
Hypoxia is a normal component of embryo development 33, and it seems to 
be one of the most important extracellular factors for lung morphogenesis 12,13 which 
is a complex process 13.  In most mammalian systems, the cellular responses to 
oxygen alterations are mediated through the hypoxia-inducible factor (HIF) family of 
transcriptional regulators 34,35. HIF complex is a heterodimer composed of one of 
three α-subunits (Hif-1α, Hif-2α, or Hif-3α) and a β-subunit (ARNT; also known as 
aryl hydrocarbon receptor nuclear translocator). In fetal lung HIF mRNA and protein 
levels are quite high 17,34,36, being the Hif-1α protein localized predominantly in the 
branching epithelium 17. These authors showed that induction of HIF-1 protein in fetal 
lung buds was sufficient to induce lung development even under non-hypoxic 
conditions, whereas its depletion, using antisense oligonucleotides, reduced lung 
branching morphogenesis and vascularization 37. The enhancement of lung epithelial 
branching morphogenesis by low oxygen has also been reported by Gebb and Jones18. 
Hypoxic environment favors anaerobic glycolysis. This metabolic phenotype 
is characterized by the switch of cell metabolism from oxidative phosphorylation to 
glycolysis, being pyruvate metabolized to lactate 38 which is then exported by MCTs 
to avoid a decrease in pHi. 
Although the contribution of MCTs to the glycolytic and acidic phenotype of 
tumours is well studied 39, their contribution to the embryo development is still not 
clear. Several studies have already suggested that embryos, as proliferating cells, 
express a metabolic phenotype similar to that of cancer cells 38. We showed that lung 
cells develop in an intermittent hypoxia environment by the expression of the hypoxia 
marker CAIX. These results are in agreement with previous studies that report 
expression of HIF during lung development 17,34.  
In order to adapt to intermittent hypoxia, cells need to create conditions to 
support embryogenesis, increasing the expression of genes related to the metabolic 
phenotype such as GLUT1 and MCT1/4 and CD147. It has also been described that 
HIF-1α up-regulates both GLUT1 and MCT4 40. Thus, with this study we show for 
the first time the expression pattern of MCT1/4 and their chaperone CD147 during 
human lung embryo development. We demonstrate that in normal fetal lung, MCT1/4 
isoforms are expressed throughout the lung development phases suggesting that these 
molecules are important for lung morphogenesis. MCT1 was seen in the 
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pseudoglandular phase in all cellular types, becoming absent in mesenchymal cells 
along gestation, being detected only in alveolar epithelium cells in later gestation, 
while MCT4 was predominantly found to be expressed throughout the various phases 
in bronchial epithelium. These results suggest that MCT1 might have a role in 
alveolar epithelium and MCT4 is more important in bronchial epithelium. CD147 
expression was similar to both MCT isoforms, however from week 18 to week 22 it is 
not detected in alveolar epithelium where MCT1 is present. This finding was 
unexpected since it has been described that MCT1/4 require this chaperone to be 
trafficked to the plasma membrane and perform their activity 41,42, which suggests the 
existence of another chaperone. We also analysed the expression of GLUT1, a 
glucose transporter widely distributed in fetal tissues that has been shown to be 
overexpress in tissues with high glycolytic rates, as well as CAIX. GLUT1 expression 
was similar to MCT4 through gestation but absent in the last phase 
(saccular/alveolar), while CAIX expression varies along gestation, starting to be 
expressed only in bronchial epithelium and being present in all epithelial cells in later 
phases. These results suggest that lungs develop in a hypoxic environment and that 
cells have the machinery to adapt to diferent levels of O2. Our results show that the 
glycolytic metabolic phenotype is more pronounced in the early phases by the 
expression of glucose transporter (GLUT1) and lactate exporters (MCT1/4). This 
phenotype continues to be detected in the bronchial epithelium during the canalicular 
phase. However, in the late stage of gestation this phenotype is attenuated. Besides 
the expression of the hypoxia marker CAIX in most of the cells, expression of MCT4 
is restricted to bronchial epithelium and GLUT1 is absent. At this level, lung tissue is 
close to complete maturation and the rates of proliferation decrease. The expression of 
CAIX at this time was not expected. Liao et al showed that CAIX was highly 
expressed during the second trimester of gestation but decreased after week 30 43. 
Several studies have already demonstrated the expression of MCTs during 
embryo development specifically during pre-implantation development of the human 
and mouse 27,28,44. Some studies showed that since the development of the zygote until 
the stage of 2 cells, there is an absolute requirement for pyruvate 45 and lactate to 
support the development of the embryo in stages of 4 and 8 cells 26,27. However, from 
stage 8 it has been observed that glucose consumption increases, being the main 
carbon and energy source to the embryo 46. The importance of MCTs has been already 
described in other organs during rat embryo development 24,47,48. Han et al 24 detected 
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MCT4 and the chaperone CD147 by immunohistochemistry during early 
cardiomyocyte differentiation and another study describes the immunoexpression of 
MCT1 and MCT2 in various cell populations of the rat forebrain, from the late 
embryonic period to the early post-natal period 47. 
In order to understand the influence of MCT inhibition in lung 
morphogenesis, studies using fetal lung explant models cultured under CHC exposure 
were performed. First, in rat tissues we confirmed the expression of both MCT1 and 
MCT4 during rat lung development. We showed that MCT1 and MCT4 were 
expressed in primitive epithelial cells as early as the pseudoglandular stage and were 
also both detected in the bronchial and alveolar epithelium cells in the remaining 
phases. The immunohistochemical results were corroborated by Western blot. For in 
vitro studies, two different doses of CHC, MCT inhibitor, were added to lung explants 
and it was observed that lung branching was inhibited with increasing concentrations 
of CHC. Morphometric analysis was performed to determine the number of peripheral 
airway buds, epithelial perimeter and total area. We observed a significant effect for 
1mM CHC in the number of peripheral airway buds. Although CHC is considered as 
a classical inhibitor of MCT activity, it can also inhibit the mitochondrial pyruvate 
transporter 49,50, This was described by Halestrap and co workers in 1974 50, however 
in this study they use isolated mitochondria. On one hand, there are no studies 
reporting the entry of CHC into cells and, on the other hand, there is evidence 
showing that CHC acts only outside the cell 50–53. Thus, we believe that effect of CHC 
in our model is mediated by inhibition of MCT activity at the plasma membrane. 
However, further experiments should be performed to clarify the true contribution of 
MCT inhibition in lung branching. Experiments with the specific inhibitor of MCT1/2 
from AstraZeneca 54 or even RNA interference approaches could be used.  
Although the role of MCTs in lung morphogenesis is still far from being well 
understood, with this study we showed that MCT inhibition disrupts lung branching, 
suggesting the dependence of these transporters for lung development. Embryonic 
developmental is strongly influenced by oxygen availability in the environment 23. 
From our results, we hypothesize that lung embryonic cells are able to survive in 
hypoxia environments adopting a metabolic phenotype to supply energy and that 
MCTs/hypoxia may have different and specific functions in epithelial differentiation 
and vascular morphogenesis. Nevertheless, further studies are needed to better 
characterize this metabolic phenotype during lung differentiation.  
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RATIONALE 
 
 
In contrast to normal differentiated cells, which rely primarily on 
mitochondrial oxidative phosphorylation to generate the energy needed for cellular 
processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed 
“Warburg effect”. This alteration allows tumour cells a rapid growth through higher 
rates of glucose consumption and lactic acid production leading to a cellular acidosis. 
To maintain high glycolytic rate and ATP production cells must efficiently export 
lactic acid 1,2. This transport is mediated by a family of proton-coupled 
monocarboxylate transporters (MCT1/4) across the plasma membrane. MCT1/4 are 
distinguished by their kinetic properties and tissue distribution and they require 
association with an accessory protein, CD147/Basigin, for trafficking to the plasma 
membrane and activity 3. 
Firstly, we analyzed the expression of these isoforms and also the chaperone 
CD147 and the glucose transporter (GLUT1) in 50 cases of lung cancer and we 
observed that all proteins were upregulated in tumour tissues when compared to non-
tumoral adjacent tissue. Moreover, we propose a series of experiments aiming to 
understand the effect of MCT1/4 inhibition by disrupting CD147. Using the 
functional genomics approach ‘Zinc-Finger Nuclease’ (ZFN) we successfully isolated 
cells knocked out for CD147, decreasing the expression and activity of both MCT1 
and MCT4. Furthermore, the disruption of CD147 sensitized tumour cells to the 
inhibition of OXPHOS by phenformin in vitro and in vivo. 
Our results demonstrate that inhibiting MCTs via CD147 disruption sensitize 
A459 tumour cells to Phenformin-induced cell death. These findings support the 
exploitation of MCTs /Bsg as therapeutic targets in lung cancer, however further 
studies, particularly development of MCTs/Bsg blockers are urgently needed. 
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3.2.1 Introduction 
 
3.2.1.1 A brief introduction to cancer 
 
Cancer is a leading cause of death worldwide 1. Based on GLOBOCAN 
2008, 12.7 million cancer cases and 7.6 million cancer deaths are estimated in 2008 
(Figure 1) 1.  
 
About 70% of all cancer deaths occurred in low- and middle-developed 
countries and death from cancer is predicted to continue to rise to over 13.1 million in 
2030 worldwide. Lung (1.6 million, 12.7% of the total for men and women), female 
breast (1.4 million, 10.9% of the total for women), colorectal (1.2 million, 9.7% of the 
total for men and women) and stomach cancers (1 million, 7.8% of the total for men 
and women) where the most common types of cancer, with more than 40% of all 
cases diagnosed 1–3. 
The principal feature of cancer is the rapid proliferation of abnormal cells 
that grow beyond their limits, and which can then invade adjacent parts of the body 
and spread to other organs. This process is referred as metastasis and this is the major 
cause of death from cancer4. Knowledge about the causes of cancer, and interventions 
to prevent and manage the disease is extensive. Strategies concerning cancer 
Figure 1: Age-standardised incidence (left panel) and mortality (right panel) of all cancers (per 
100.000; all ages; excluding non-melanoma skin cancer), according to GLOBOCAN 2008 1. 
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prevention or early detection can reduce and/or control cancer progression. In fact, 
many cancers have a high chance of cure if detected early and treated adequately 5. 
 
ü Lung cancer: Epidemiology and Risk factors 
 
Non-small cell lung cancer (NSCLC) is one of the most common cause of 
death from cancer worldwide, with 29% of all male cancer deaths and 26% of all 
female cancer deaths in 2009 (Figure 2) 3. The overall 5-year survival rate of patients 
with metastatic disease is less than 15% 1,6. This is due to the history of lung cancer, 
which has a rapid rate of growth when compared with other cancers1.  
 
Since exposure to risk factors such as smoking, only results in disease after 
several years, lung cancer incidence and mortality for women and men tends to reflect 
prior and long-term exposure to risk factors. In developed countries, the incidence of 
Figure	  2:	  Estimated	  new	  cases	  (upper	  painel)	  and	  estimated	  deaths	  (lower	  painel)	  of	  all	  types	  of	  cancers	  for	  	  men	  and	  women	  3	  .	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lung cancer in men has reached a plateau and is now decreasing, whereas the number 
of new cases in women continues to increase 1,3, while in less developed countries 
male lung cancer incidence is continuing to increase. Besides tobacco smoking, 
exposure to radon gas, asbestos and other chemicals, environmental pollution and 
employment-related risks in certain industrial settings, constitute also risk factors to 
develop lung cancer. However, tobacco smoking is the most important risk factor for 
cancer, causing 22% of global cancer deaths and 71% of global lung cancer deaths 7,8. 
  
ü Lung cancer: Classification 
 
Based on the histologic features and response to conventional therapies, lung 
cancer has been divided into 2 major categories: non-small cell lung carcinoma 
(NSCLC) and small cell lung carcinoma (SCLC)9. NSCLC is further divided into 
three major types, squamous cell carcinoma (SCC), adenocarcinoma (AC) and large 
cell carcinomas. Large cell carcinomas represent poorly or undifferentiated forms and 
the criteria for its diagnosis vary widely, thus, for these reasons, we will focus on the 
squamous cell carcinoma and adenocarcinoma subtypes of NSCLC and combine large 
cell, poorly differentiated, undifferentiated and not otherwise specified NSCLC as 
“other types”. 10 
 
 
ü Lung cancer: Treatment  
	  
Lung cancer treatment requires a careful selection of one or more 
intervention, such as surgery, radiotherapy, and chemotherapy that can vary according 
to tumour stage 9. The treatment options for most patients with NSCLC are not 
different between SCC or AC histologic subtypes. Only early-stage patients will 
benefit on having treatment based on surgery or radiotherapy/chemotherapy 2. 
Advanced NSCLC may also have biological therapy such as erlotinib (Tarceva), 
gefitinib (Iressa) or crizotinib (Xalkori), however, this type of treatment requires 
certain parameters 11.  
The goal is to cure the disease or considerably prolong life while improving 
the patient's quality of life. Genetic profiles or individual molecular characteristics of 
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lung cancer have been known for many years but have failed to make much impact on 
the clinical setting, until recently 12. Important molecular drivers, that can characterize 
a subsets of lung cancers, mainly adenocarcinomas, have been identified in the last 
years 13. Mutations in epidermal growth factor receptor (EGFR), KRAS, and 
anaplastic lymphoma kinase (ALK) are mutually exclusive in patients with NSCLC, 
and one of these mutations can predict the response to targeted therapy (18). 
Tyrosine-kinase inhibitors (TKIs), namely erlotinib and gefitinib, which act on EGFR 
have become important drugs in the treatment of advanced NSCLC and were 
approved in many countries for the treatment of locally advanced or metastatic 
NSCLC as a second- or third-line regimen 14. Further investigation demonstrated that 
a better response to this therapy is observed in patients harbouring EGFR mutations, 
particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X 7,15. These 
mutations are commonly observed in female Asian descent patients, with 
adenocarcinomas and no prior history of smoking 7. Other TKI used in NSCLC is 
crizotinib that acts on ALK rearrangements that are more common in nonsmokers or 
light smokers patients with adenocarcinoma 16. Bevacizumab (Avastin), a monoclonal 
antibody which inhibits angiogenesis via acting on the vascular endothelial growth 
factor A (VEGF-A) was also approved by U.S. Food and Drug Administration (FDA) 
for use in first-line treatment for NSCLC combining with chemotherapy agents 17. 
Moreover, inactivating point mutations, homozygous deletions or promoter 
hypermethylation at the tumour suppressors LKB1, BRG1, MYC, PTEN, P16, RB are 
now becoming part of the landscape of lung cancer classification 18 (figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Frequency of mutations at the indicated genes in lung tumours (including all 
histopathologies) of sporadic origin 18. 
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The selection of individual patients for specific treatment strategies will then 
depend not only on clinical characteristics but also on tumour biology. A better 
understanding of the molecular mechanisms driving lung tumourigenesis is crucial 
and will provide enormous benefits in developing new pharmacological treatments. 
 
3.2.1.2 MCTs in Cancer 
Although lactate transport via MCTs is important in metabolism in a variety 
of biological systems under normal physiological conditions, MCT1 and MCT4 are 
commonly overexpressed by cancer cells to maintain intracellular lactate and pH 
homeostasis 19. Taking in account the tumour microenvironmental scenario and 
molecular events that occur in carcinogenesis, it is possible to predict the importance 
of these lactate transporters in cancer. Tumours cells are characterized by an 
excessive anaerobic glycolysis that is a hallmark of cancer cells and leads to 
accumulating of glycolytic intermediates, including precursors of nucleic acids, lipids 
and proteins that contribute to rapid cell proliferation 20,21. As already described in 
Chapter 1, the higher consumption of glucose and consequently a higher production 
of lactate is a constant feature in most cancers, therefore it is required an abundant 
expression of glucose transporters and glycolytic enzymes 22–24. Also, an effective 
lactate extrusion mechanism to avoid lactic acidosis is necessary, which could act by 
a feedback mechanism to inhibit glycolysis 25. In this context, many cancer cells 
overexpress MCTs (Table 1 26).  
The first report on MCT expression in human tumour samples was described 
in 1998 by Ritzhaupt and his co-workers 27. They observed that MCT1 expression 
decreased in the transition from normal colon to malign tissue. Later evidence showed 
a high expression of MCTs in colon carcinoma 28–30. Pinheiro et al document MCT1 
and MCT4 in the plasma membrane of colorectal cancer cells accompanied by a 
decrease in MCT2 at the plasma membrane 29. This finding is in accordance with the 
dependence of glycolytic cancer cells in exporting lactate through MCT1 and MCT4, 
but not MCT2. Additionally, MCT1 and/or MCT4 expression was also detected in 
lung, breast, brain, prostate, head and neck, ovarian, cervical cancers and others 
28,29,31–44. Importantly, MCT expression was also correlated with several clinic-
pathological data. Plasma membrane MCT1 expression in colon cancer was 
associated with vascular invasion 29. 
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Table 1: (cont) 
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In breast cancer MCT1, alone or in co-expression with CD147, was associated 
Table 1: (cont) 
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with basal-like subtype (a more aggressive breast cancer group) and other poor 
prognostic variables, including high tumour grade 45. Moreover, MCT1 and MCT4 
were significantly associated with high FIGO stage, presence of residual tumour, lack 
MCT4 expressions were associated with high PSA levels, high Gleason score, high 
pathological stage, and nodal involvement 31,46. In contrast to what was found in the 
previous types of tumours, neither MCT1 nor MCT4 were found to be up-regulated in 
gastric adenocarcinomas 47. Regarding lung cancer the literature is controversial. 
Koukourakis and co-workers firstly observed overexpression of MCT1, 2 and 4 in 
cancer cells 35. No expression of MCTs in normal lung was found, while MCT1, 
MCT2 and MCT4 were expressed in cancer cells. This study also analyzed the 
metabolic cooperation between lung cancer cells and tumour-associated stroma, 
however, tumour-associated stroma expressed MCTs weakly. In opposition, a recent 
study by our group showed that normal lung presents a high frequency of MCT 
expression and, in fact, MCT4 is less expressed in tumour samples than in normal 
epithelium 28. However, as this last study was performed in a small number of cases, 
further work is needed to confirm these results 28. Another study showed the spatial 
distribution of MCT4 in 90 NSCLC cases. They observed that MCT4 expression was 
relatively high in the first cell layers around the vessels in adenocarcinomas whereas 
its upregulation was stronger in hypoxic areas in squamous cell carcinomas 48. MCT1, 
in association with its chaperone CD147, was also described in the cytoplasm of 
alveolar soft part sarcomas 49.  
 
ü Targeting MCTs in cancer 
Considering the crucial role of MCTs in cancer, these lactate transporters are 
appealing targets for cancer therapy. Sonveaux and co-workers 50 described the cell-
cell lactate shuttle in cancer, where MCT1 has a crucial role by importing lactate into 
oxidative cells. Thus, targeting MCT1 will have important implications in cancer 
homeostasis (Figure 4). Also, inhibition of MCTs will have a direct effect in lactate 
transport, interfering with pHi homeostasis and also with acidic microenvironment. 
In fact, there are already in vitro studies showing inhibition of MCTs in 
several human cancer cell lines. Thus, MCT1 inhibition has been shown to decrease 
intracellular pH 41,50, cell proliferation and migration 33 cell invasion 33,36, leading to 
cell death 33,40,41,50,51 and inducing cancer cell radiosensitivity 51. 
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Downregulation of MCT4 results in decreased cancer cell migration 52, by 
mechanisms that also involve its interaction with with β1-integrin in breast cell line 52. 
Promising results using in vivo models have already been reported. Administration of 
CHC, MCT1 inhibitor (Chapter 1), retards tumour growth 33,50, renders tumour cells 
sensitive to radiation 50, induces tumour necrosis and decreases tumour invasion 53. 
Moreover, targeting both MCT1 and MCT4 by themselves or through the chaperone 
CD147, also reduced tumour growth and glycolytic flux in vivo 54.  In what concerns 
lung cancer cells, Izumi and co-workers showed that inhibition of MCT1 or MCT4 
inhibited cancer cell invasion but did not influence cell migration 55.  
 
ü MCT regulation by chaperones in cancer  
As mentioned in Chapter 1, accessory proteins, such as CD147, regulate the 
functional expression of MCTs. CD147 also known as extracellular matrix 
metalloproteinase inducer (EMMPRIN), HAb18G/CD147 or basigin (BSG) belongs 
Figure	  4:	  Model	  for	  therapeutic	  targeting	  of	  lactate-­‐based	  metabolic	  symbiosis	  in	  tumors	  46.	  Hypoxic	  tumor	  cells	  depend	  on	  glucose	  and	  glycolysis	   to	  produce	  energy.	  Lactate,	   the	   final	  product	  of	  glycolysis,	  diffuses	  toward	  blood	  vessels	  and	  oxygenated	  tumour	  cells	  import	  lactate	  by	  MCT1	  that	  is	  located	  at	  the	  cell	  plasma	  membrane	  and	  oxidize	   it	   to	  produce	  energy.	   In	  the	  respiration	  process,	   lactate	   is	  a	  substrate	  preferred	  to	  glucose.	   As	   a	   consequence,	   glucose	   freely	   diffuses	   through	   the	   oxygenated	   tumor	   cell	   sheath	   to	   fuel	  glycolysis	  of	  distant,	  hypoxic	   tumor	   cells.	  This	  metabolic	   symbiosis	   can	  be	  disrupted	  by	  MCT1	   inhibition.	  Upon	  MCT1	  inhibition,	  oxidative	  tumor	  cells	  switch	  from	  lactate	  oxidation	  to	  glycolysis,	  thereby	  preventing	  adequate	   glucose	   delivery	   to	   glycolytic	   cells,	  which	   die	   from	   glucose	   starvation.	   This	   glycolytic	   switch	   is	  associated	   with	   a	   decrease	   in	   oxygen	   consumption	   of	   surviving	   tumor	   cells,	   which	   is	   responsible	   for	  increased	  tumor	  pO2.	  GLUT,	  glucose	  transporter.	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to the immunoglobulin (Ig) superfamily, is a heavily glycosylated type I 
transmembrane glycoprotein 56,57 and is widely distributed and expressed in high 
levels in many tissues, mainly in metabolically active cells such as lymphoblasts and 
malignant tumour cells 56,58. CD147 is also involved in reproduction and 
development. Its best characterized function is stimulation of matrix 
metalloproteinase (MMP)-production 57 in stromal fibroblasts and endothelial cells, 
leading to extracellular matrix degradation and metastasis 57,59. CD147 has also an 
impact on tumour growth, mediates chemoresistance 60–63 and stimulates VEGF 
expression, inducing angiogenesis 57,64. The crystal structure of CD147 indicates that 
it is composed by an extracellular domain, a transmembrane domain (TMD) and a 
cytoplasmic domain 57. The extracellular portion of basigin comprises an N-terminal 
IgC2 domain and a membrane-proximal IgI domain 65. The IgC2 domain is required 
for counter-receptor activity, which is involved in MMP induction and 
oligomerization 66,67 while, the IgI domain is required for association with caveolin-1, 
that regulates cell surface clustering 68. 
 
Figure	   5:	   Structures	   of	   the	  basigin	   gene	   and	  protein	   isoforms.	  The	   basigin	   gene	   expresses	   4	   splice	  variants	   and	   contains	   an	   alternative	   promoter.	   Black,	   coding	   sequence;	  white,	   noncoding	   sequence.	  The	  double	  lines	  represent	  disulfide	  bonds.	  Si34	  and	  Si219	  represent	  the	  RNA	  interference	  target	  sites.	  HAb18,	  B23ID,	  and	  B4N11	  indicate	  the	  binding	  sites	  of	  the	  antibodies	  62.	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Currently, four basigin alternative splicing transcript variants are described, 
encoding four different protein isoforms (basigin 1, 2, 3 and 4) (Figure 5).  
The basigin-1 transcript (NM_001728) encodes the retina-specific isoform 
that is distinguished by an additional Ig-like domain (three Ig-like domains in total) in 
the extracellular portion.  The basigin-2 transcript (NM_198589) encodes the well-
known basigin/ CD147/EMMPRIN 69. 
Basigin-3 (NM_198590) and basigin-4 (NM_198591), the isoforms less 
common, were first identified in human endometrial stromal cells and cervical 
carcinoma cell lines 70. Basigin-3 is a short isoform comprising only one Ig-like 
domain (Ig-I domain) and interacts with the internalized basigin receptor-ligand 
complex. This isoform exerted an inhibitory function in proliferation and invasion of 
hepatocellular carcinoma cells, probably via hetero-oligomerization with basigin-2 71. 
Basigin-4 is overexpressed in cervical cancer and promotes proliferation of cervical 
cancer cells. Evidence shows that basigin-2 is highly expressed in normal heart, 
kidney, skeletal muscle and testis. Basigin-3 is highly expressed in the bone marrow, 
fetal liver, lung, testis and thymus, and the tissue expression profile of basigin-4 is 
similar to that of basigin-3 66.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  6:	  Monocarboxylate	  transporter	  1	  (MCT1)	  and	  CD147	  predicted	  interaction.	  This	  interaction	  is	   proposed	   to	   involve	   an	   arginine	   residue	  within	   the	   transmembrane	   segment	   8	   of	   MCT1	   and	   a	  glutamic	  acid	  residue	  in	  the	  transmembrane	  segment	  of	  CD147	  68.	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The TMD of CD147 contains a glutamic acid residue, which is involved in the 
association of the protein to the plasma membrane (Figure 5)72. This residue forms a 
charged-pair with a positive residue in a TMD of MCTs 73. Evidence implicates 
Arg306 in TMD8 (numbering based on rat MCT1) as a potential candidate for such a 
charged-pair. Acting as an essential chaperone, CD147 leads to the correct activity 
and targeting of MCTs to the plasma membrane 74. 
CD147 is a multifunctional protein and its elevated expression is reported in 
various cancers such as in lung, breast, brain, prostate, ovarian and others 31,75–87. It 
has been shown that higher expression of basigin was associated with poor prognosis 
of cancer patients and could serve as an independent predictor of poor survival in 
cancer 82,85.  
Le Flock and co-workers demonstrated that the major pro-tumoural action of 
CD147/Basigin is mediated by its cardinal function of chaperoning MCTs, a central 
action in energy metabolism particularly in highly glycolytic tissues 54. In fact, there 
are several studies showing the regulation of MCTs by CD147. Several results show 
that CD147 and MCTs are co-expressed in human cancer tissues 28,31,33,34,45,47,86. 
Moreover, results published by our group showed that the prognostic value of CD147 
appears to be associated with its co-expression with MCT1 in breast cancer 47. 
Therefore, targeting CD147 to inhibit MCTs appears to be a rational approach. In this 
context, CD147 silencing has been reported to inhibit MCT1/MCT4 function, 
decreasing lactate export 88 and consequently decreasing pHi 54,89,90 and reducing the 
malignant potential of cancer cells in vivo 54,90.  
An enhancement of glycolysis, a cellular pathway that produces both energy 
and precursors of macromolecules, is a classic metabolic hallmark of cancer, making 
this pathway an attractive target for therapy 21. With the established roles of MCTs in 
lactate extrusion and pH homeostasis, it is perhaps not surprising that blocking MCT1 
and MCT4 in cancer cells impacts tumour growth. However, tumour cells have the 
ability to adapt to alterations and switch to a different metabolic program. It is 
therefore important to understand cell metabolism mechanisms, since a single 
molecule may not be an important piece of the puzzle. Therefore, efforts to explore 
new strategies to target these metabolic pathways are crucial to develop effective 
anticancer therapies, namely the inhibition of more than one bioenergetic pathway. 
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This Chapter describes the experiments performed to clarify the importance 
of MCT1 and MCT4 in lung cancer. First we analyzed the expression of these 
isoforms and also the chaperone CD147 and the glucose transporter (GLUT1) in 50 
cases of lung cancer. We observed that all proteins were upregulated in tumour tissues 
when compared to non-tumoural adjacent tissue. Afterwards, we evaluated the effect 
of MCTs inhibition through targeting CD147 on cancer cell viability. Preliminary 
results in the laboratory using RNA interference approach showed that knockdown of 
CD147 or MCT4 in the presence of iMCT1/2 inhibitor sensitized cells to the ablation 
of oxidative phosphorylation (OXPHOS) with olygomicin. However, these effects 
were reversed in hypoxia with the upregulation of the remaining protein of MCT4 and 
CD147. Thus, we decided to adopt an approach to knockout (KO) CD147 gene. Using 
the zinc finger technology we knocked-out CD147 in an adenocarcinoma lung tumour 
cell line. We observed that the disruption of CD147 decreased the expression and 
activity of both MCT1 and MCT4 and this disruption sensitized tumour cells to the 
inhibition of OXPHOS by phenformin in vitro and in vivo. 
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3.2.2 Material and Methods 
 
3.2.2.1 Tissue samples 
Representative formalin-fixed paraffin-embedded samples from primary lung 
tumour tissues were retrieved from pathology archives of the Department of 
Pathology of Hospital S. João, Porto, Portugal. The tumours were classified according 
to the WHO criteria 9. This cohort includes 50 cases of non-small cell lung cancer 
(NSCLC), being 8 squamous cell carcinomas (SCC), 29 adenocarcinomas (AC) and 
13 from other types. Non-tumoural adjacent tissue from each case was also selected.  
 
3.2.2.2 Cell Line 
In the present study we used the lung adenocarcinoma cell line A549 
obtained from ATCC (American Type Culture Collection), which was maintained in 
Dulbecco’s modified eagle medium (DMEM, Gibco) supplemented with 10% fetal 
calf serum (FCS - Gibco), penicillin (10 units/mL) and streptomycin (10 µg/mL), in a 
humidified atmosphere of 5% CO2 at 37 °C.  
 
3.2.2.3 Immunohistochemistry (IHC) 
Sections of 3-µm were used for Immunohistochemical analysis. IHC for 
MCT1 and CD147 was performed according to the avidin-biotin-peroxidase principle 
(R.T.U. Vectastin Elite ABC kit; Vector Laboratories), as previously described by our 
group 33. MCT4, GLUT1 and CAIX IHC was performed with the Ultravision 
Detection System Anti-polyvalent, HRP (Lab Vision Corporation), as previously 
described 32,33. In brief, paraffin embedded sections were deparaffinized in xylene and 
hydrated in a graded series of ethanol solutions. For antigen retrieval, slides were 
incubated either with 1mM EDTA buffered solution, pH 8.0 (CD147) or citrate 
buffer, pH=6 (MCT1, MCT4, GLUT1 and CAIX) for 20 min in water bath at 98°C. 
After endogenous peroxidase inactivation, incubation with the primary antibody was 
performed overnight for MCT1 and CD147 and 2 h for MCT4, GLUT1 and CAIX at 
room temperature. Tissues were stained with 3,3’-diamino-benzidine (DAB+ 
Substrate System, DakoCytomation) and counterstained with haematoxylin. Colon 
carcinoma tissue was used as positive control for MCT1, MCT4, CD147 and GLUT1 
and normal stomach tissue for CAIX. Stained slides were evaluated and then 
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photographed under a bright field microscope. Sections were scored for plasma 
membrane expression following a semi-quantitative criterion. The score used was the 
sum of the percentage of positive cells (0, negative; 1, less than 25% positive cells; 2, 
26% to 50% positive cells; and 3, more than 50% positive cells) and the staining 
intensity (0, negative; 1, weak; 2, moderate; 3, strong). Scores between 0 to 3 were 
classified as negative and 4 to 6 as positive 29.  
 
3.2.2.4 Generation of bsg-null cells using Zinc Finger Nuclease 
Zinc-finger nucleases (ZFNs) are a class of engineered DNA-binding 
proteins that have redefined genome engineering. The ZFNs plasmids bind a specific 
DNA sequence inducing a double strand break (DSB). This break is repaired by the 
non-perfect endogenous repair mechanism called non-homologous end joining 
(NHEJ). The DBS will be misrepaired by the addition and/or deletion of nucleotides. 
This disruption results in a knockout, in a non-sense gene product and the loss of gene 
function 91.  
 
 
 
The ZFN structure consists of a DNA binding domain – zinc finger protein 
(ZFP) - linked to a nuclease domain of the FOK1 restriction enzyme 92. The ZFP 
region contains a tandem array of Cys2-His2 fingers that each recognizes 3bp of DNA. 
Figure	  7:	  ZFN-­‐mediated	  genome	  editing	  takes	  place	  in	  the	  nucleus	  when	  a	  ZFN	  pair	  targeting	  the	  user’s	  gene	  of	  interest	  is	  delivered	  into	  a	  parental	  cell	  line,	  either	  by	  transfection,	  electroporation	  or	  viral	  delivery	  86.	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This domain can have from 3 to 6 fingers binding to a target of 9bp to 18bp 
respectively. The catalytic domain composed by the enzyme FOKI requires 
dimerization to cut thus, a pair of ZFNs is required. The dimerization avoids cleavage 
at single binding sites (Figure 7) 93.  
To generate null cells, first two plasmids targeting basigin exon 2 encoding 
signal peptide of basigin splice variants 1 and 2 were designed and obtained from 
Sigma-Aldrich. A549 cells (1x106 cells/100-mm dishes) were transfected using 
JetPRIME® DNA & siRNA Transfection Reagent (Polyplus-transfection SA), 
according to the manufacturer’s instructions. Briefly, 10 µg of DNA (5µg of each 
ZFN plasmid) were diluted in 500µl of jetPRIME® buffer and mixed.  20 µl of the 
jetPRIME transfection reagent were added to the first. After vortexing and a spin 
down, the mixture incubated for 10 min was added drop-by-drop to the cells and 
mixed gently. After 6 hours of transfection, the media was replaced by fresh media. 
One week after, transfected cells negative for bsg were selected and sorted by 
Fluorescence-activated cell sorting (FACS). First, cells were stained for bsg and 
passed through the FACS. Individual clones were plated in 96 well plates and allowed 
to grow until confluence. Single colonies were trypsinised and expanded in duplicate 
wells, one of which was frozen and the other was allowed to grow to propagate the 
clone. A pharmacologic pre-selection was performed by adding 1 mM of the drug 
metformin to each clone. Metformin is a drug from the biguanide class that impairs 
OXPHOS. Thus, the putative negative clones, the ones that have disruption of 
CD147/basigin and consequently decreasing of lactate export (glycolysis inhibited), 
will die after blocking respiration. For these clones, sensitive to metformin, protein 
was extracted with Laemmli buffer 1,5x (Bio-Rad Laboratories, CA) and negative 
expression for basigin was confirmed by Western blot.  
 
3.2.2.6 Sequencing of the ZFN Cutting Site 
Genomic DNA from A549 wt and bsg -/- cell was extracted and amplified by 
PCR with primers that surround the ZFN cutting site. The primers are: (sense) 5’-
TTGGAGGTTGTAGGACCGGCGA-3’, (anti-sense) 5’- 
CAAGCTCCATGCTGGCGC-3’. PCR reaction was carried out in a total volume of 
20 µl, consisting of 200 ng of gDNA, 0.5 µM of both sense and anti-sense primers 
(sent with the ZFN kit), 200 µM of dNTPs, 1,5 mM of MgSO4, 1 × Taq Buffer and 10 
Chapter 3 
	  106	  
U of KOD hot start DNA polymerase (all the reagents from Novagene). The reaction 
consisted of an initial denaturation at 95 °C for 3 min, followed by 31 cycles with 
denaturation at 95 °C for 10 s, annealing at 68 °C for 30 s and extension at 68 °C for 
30 s, followed by a final extension 3 min at 68 °C.  
 
3.2.2.7 [14C]-Lactate Uptake 
The [14C]-lactate uptake was measured to determine lactate transport, 
according to the previously published 54. Briefly, cells were seeded in 35-mm dishes 
and equilibrated for 5 min in 20 mM buffered glucose-free and HCO3−-free saline 
solution containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, adjusted 
to pHe 6.0 in the presence or absence of iMCT1/2 (300 nM). The solution was then 
replaced by the same solution containing 0.2 µCi /mL of [14C]-L-lactate (100 µM; 
Amersham Biosciences). Uptake was stopped by washing four times with ice-cold 
PBS. Cells were lysed with 250 µL of 0.1 M NaOH. The radioactivity was determined 
by mixing 750 µL of scintillation liquid with 200 µL of cell lysate and counted with a 
liquid scintillation counter (Wallac). The protein concentration was determined to 
normalize radioactivity to the protein content of the cells in each dish. [14C]-L-lactate 
uptake was expressed as counts per million per milligram of protein. 
 
3.2.2.8 Determination of Intracellular Lactate Concentration.  
Cells (3x105) were seeded in 12-well plates and allowed to adere overnight. 
After incubation either in normoxia or hypoxia of 1% O2 for 24h, cells were washed 
twice and maintained in DMEM without glucose, pyruvate and serum for 2 hours 
with either DMSO or MCT1/2 inhibitor (300nM). After that, regular DMEM 5% 
serum with either DMSO or MCT1/2i cells were collected at the indicated times (0h; 
1h; 3h; 6h). For estimation of intracellular lactate, cells were washed once with cold 
PBS1x and cold water and lyzed with 200 µl cold water, while for extracellular 
lactate, the supernatant of each condition was collected at the same time points. 
Lactate concentration was determined using the Lactate colorimetric assay kit 
(Biovision Incorporated). 
 
3.2.2.9 Western blot 
Cells were lyzed in Laemmli 1,5x buffer and incubated for 15min at 95°. 
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Protein concentrations were determined using the BCA Assay. 40 µg of protein of 
each sample were separated on 8% SDS polyacrylamide gels and transferred onto 
polyvinylidene difluoride membranes (Millipore). After that, membranes were 
blocked with 5% milk in TN buffer (50mM Tris-HCl pH7.4, 150mM NaCl) for 1h 
and then incubated overnight at 4°C with the primary antibodies for Bsg/CD147 
(1/500; R&D Systems; MAB972), HIF-1α,ref MCT4 (1:1000; H-90; sc-50329; Santa 
Cruz Biotechnology) and for MCT1 (rabbit polyclonal antibodies against the C-
terminal last 15 residues prepared by the laboratory). ARD1 was used as loading 
control. After washing with TN buffer with 1% Triton-X100 and incubated with 
secondary antibody coupled to horseradish peroxidase, bands were detected with the 
ECL system (Amersham Biosciences). 
 
3.2.2.10 Clonogenicity assay 
A549 wt and bsg -/- cells (2x103) were seeded in 60-mm dishes and 
incubated for 24h to attached. Medium was replaced by regular DMEM 10% serum 
with and without iMCT1 (300 nM) or Phenformin (50uM) or both for 10 days in 
normoxia and 15 days in hypoxic (1% O2) conditions. Cells were stained with 
Giemsa (Fluka).   
 
3.2.2.11 Measurement of Glycolysis and Oxygen Consumption 
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) 
were measured with a Seahorse XF analyser (Seahorse Bioscience). 8x104 cells were 
seeded in seahorse plates and allowed to grow for 24h. Plates were incubated for 45 
min in a non-CO2 incubator at 37°C with seahorse medium without glucose and 
pyruvate before measurements. Then glucose (10 mM), MCT1i (AZ) (1uM, 
phenformin 50uM and olygomycin were injected and three measurements after each 
addition were undertaken determining oxygen and proton concentration in the 
medium. In the end, all media were removed and protein concentration was 
determined to normalize OCR and ECAR values.  
 
 
3.2.2.12 Tumour Xenografts 
Immunodeficient female nude mice with approximately 22 g body weight 
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were housed in groups of 5 under specific pathogen-free, controlled ambient 
conditions. Animal studies were conducted according to Centre National de la 
Recherche Scientifique institutional guidelines. A549 wt and bsg-/- cells 
(2x106/mouse) suspended in 500 µL of serum-free DMEM supplemented with 
insulin-transferrin-selenium (Gibco) were sub-cutaneously injected into the backs of 
the mice. Water containing 6% sucrose with and without 200mg/Kg phenformin was 
added to the drinking water, and the daily intake fluids were monitored. Fresh 
phenformin was administered every two days.  Tumours were measured every 2–3 
days using a calliper and volume was determined by using the formula: (4π/3) × L/2 × 
W/2 × H/2, where L represents length, W the width, and H the height. Tumours were 
harvested at approximately 1 cm3. 
 
 
3.2.2.13 Statistics 
For the in vitro studies, the GraphPad prism 5 software was used, with the 
Student’s t-test, considering significant values to be p<0.05. 
  
Role of MCTs in lung cancer 
	  
	  109	  
 
3.2.3 Results 
 
3.2.3.1 MCTs expression in lung tumours 
In the present study we aimed to evaluate the effect of MCTs/CD147 
inhibition in lung tumour cell lines. First of all, we went to analyse in a series of 
human lung cancer the expression of these biomarkers. We studied 50 cases of non-
small cell lung cancer (NSCLC). The series comprehend squamous cell carcinoma 
tumours (n=8), adenocarcinomas (n=20) and others types (12). All the cases have 
non-tumoural adjacent tissue available that was also studied. We observed that 
MCT1, MCT4 and CD147 were significantly overexpressed in tumour samples when 
compared to non-tumoural adjacent tissue (Figura 8). 
 
 
According to the WHO, the histological types more common are the 
squamous cell carcinomas and adenocarcinomas. Protein levels were distinct between 
these two hystological types. MCT1 and MCT4 were expressed in all squamous cell 
Figure 8: Immunohistochemical expression of monocarboxylate transporters, MCT1 and MCT4, and their 
chaperone protein CD147 in lung cancer samples. All markers were upregulated at the plasma membrane of 
tumour cells. Pictures were obtained using the microscope Olympus BX61, at 400× magnification 
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carcinoma type cases, being CD147 expressed in 60% of the cases. Regarding 
adenocarcinoma tumours we observed that MCT1 was expressed in 30%, MCT4 in 
20% and CD147 in 40% (Table 2). After confirming the expression of these 
biomarkers in lung tumours and taking into account the overlapping activity of both 
MCT1 and MCT4, we decided to evaluate the effect of MCTs inhibition by disrupting 
their chaperone CD147 in a lung cancer cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3.2 Expression of MCT1, MCT4, and CD147 in A549 
adenocarcinoma cell line 
A549 cells expressed MCT1, MCT4 and CD147, however, with distinct 
levels, as detected by Western blot. Under normoxia conditions, cells express lower 
levels of MCT4 and CD147. Under hypoxia conditions (1% O2), cells overexpress 
MCT4 and consequently the chaperone CD147 (Figure 9A). The expression of all 
markers was mainly present in the plasma membrane (Figure 9B). 
 
Table 2: Monocarboxylate transportes (MCT1 and MCT4) and CD147 expressions in 
non-tumoural and lung cancer tissues 
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3.2.3.3 Generation of CD147 -/- Cell Lines using ZFNs 
To assess the role of MCTs we decided to disrupt CD147. Thus CD147 was 
knocked out in the A549 lung adenocarcinoma cell line using CompoZrTM ZFNs 
custom-designed to introduce double-strand breaks at a genomically unique target site 
in exon 2 encoding signal peptide of CD147 splice variant 2. Clones isolated were 
screened by Western blot for the absence of CD147 expression. From around 60 
clones screened, in approximately 10 CD147 protein was not detectable and some 
appeared to show reduced CD147 protein expression, possibly due to the cut of a 
single allele (Figure 10A lines 4 and 5)). Two candidates knocked-out (Clone 153 and 
113) (Figure 10A) were identified and selected for further characterization. The cut 
site was amplified by PCR and sequences and mutational status was confirmed by 
sequencing. First, we analysed the expression of MCT1 and MCT4 isoforms in 
normoxia and hypoxia 1% O2 conditions. By immunoblotting, we observed that 
MCT1 protein was not detectable in CD147-/- cells compared to wild type, while 
Figure 9: Monocarboxylate transporters (MCT1 and MCT4) and CD147 expressions in A549 cell line A: 
Western blot analysis of MCT1, MCT4 and CD147 in A549 cell line exposed to normoxia (N) and hypoxia 
1% O2 (H) for 48 and 72 hours. ARD1 was used as a loading control. B: Immunocytochemistry analysis of 
MCT1, MCT4, and CD147 expressions in A549 wt cells (400× magnification). All the markers were mainly 
present at the plasma membrane. 
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MCT4 expression was reduced. We also observed that, besides in a lesser extent, the 
remaining MCT4 in CD147 -/- cells is induced in hypoxia. By qPCR, we demonstrated 
low transcript expression of CD147 but no evidence for changes in expression of 
MCT1. MCT4 expression appeared to increase 2-fold in CD147-/- cells (Figure 10B). 
There were no changes in cell morphology and proliferation between parental and 
CD147-/- cells (Figure 11A and 12). 
 
 
3.2.3.4 CD147 disruption inhibits MCTs activity 
We then went to measure the activity of lactate transport in both conditions. 
The uptake of 14C-lactic acid was measured with and without the presence of the 
MCT1/2 inhibitor AR-C155858 (Figure 11B). We demonstrated that the ability of 
MCT1 to transport lactate is completely suppressed in CD147 KO cells while for 
MCT4 decreased 58% when compared to wt cells. The transport activity was also 
evaluated by analysing the intracellular lactate accumulation (Figure 11C). Both cells 
lines were cultured with 25mM of glucose and in the presence or absence of the 
MCT1/2 inhibitor and intracellular lactate was measured for 1h, 3h and 6h. Results 
for CD147 cells without treatment showed a higher intracellular lactate accumulation 
and upon MCT1 inhibitor exposure this significantly increased when compared with 
wt cells. These results indicate that CD147 disruption, in addition to decrease in MCT 
expression, more importantly disturbs their activity.  
Figure 10:  : Monocarboxylate transporters (MCT1 and MCT4) and CD147 expressions in A549 wt and CD147-/- 
cells. A: Western blot analysis of MCT1, MCT4 and CD147 in A549 cell line wt and CD147-/-  exposed to 
normoxia (N) and hypoxia 1% O2 (H) for 48 hours. ARD1 used as a loading control. B: mRNA levels of MCT1, 
MCT4 and CD147 in wt and CD147-/- cells (Clone 153 and 113) in hypoxia 1% O2. The KO of CD147 did not 
influence with the transcritption of MCT1 and MCT4. 
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Figure 11: Effect of CD147 disruption on total cell biomass, MCTs activity and cellular metabolism. A: Total 
biomass of A549 wt and CD147-/- (Clone 153 and 113) cells was evaluated over time by the sulphorhodamine B 
assay. B: [14C]-Lactic acid uptake of A549 wt and CD147-/- cells in the absence or presence of iMCT1/2 (300nM) 
in hypoxia 1% O2 . C: Time-course of intracellular lactate concentration in response to glucose (25 mM) addition 
in the presence of DMSO or iMCT1/2 (300nM). (*** p <0.0001) 
 
 
3.2.3.5 MCTs inhibition sensitize cells to phenformin in hypoxia 
To understand the energy metabolism of tumour cells and the interplay 
between the two main bioenergetic pathways, glycolysis and OXPHOS were inhibited 
with the inhibition of MCTs and phenformin, respectively. There is evidence that 
phenformin and metformin have anticancer effects. Regarding proliferation, there 
were no differences between A549 wt and CD147 -/- cells and colony morphology was 
also similar (Figure 12). In the same way, the growth and survival were not affected 
by the MCT1/2 inhibitor AR-C155858 in normoxia and hypoxia 1% for both cell 
populations. However, when in normoxia conditions, OXPHOS was inhibited with 
both phenformin and metformin wt cells growth was suspended and for CD147 -/- 
cells a significant loss of clonogenicity was observed, with no further change in 
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colony size (Figure 12). In hypoxia, where MCT4 is upregulated, only wt cells grew 
and survived (Figure 12). The combination with MCT1/2 inhibitor did not give any 
additional result. To further confirm these results we used the mitochondrial ATP 
synthase inhibitor olygomicin (data not shown). To note that wt cells were more 
sensitive to the phenformin effect. To support these effects on the bioenergetic 
pathways, we also evaluated aerobic glycolysis and OXPHOS using a Seahorse XF24 
Extracellular Flux Analyser (Figure 13A and B).  
 
A549 wt and CD147-/- cells were assayed in unbuffered seahorse media and 
extracellular acidification rates (ECAR) and oxygen consumption rates (OCR) were 
Figure 12: Clonal growth of A549 wt and Bsg-/- cells in the presence or absence of MCT1/2i 
(300nM), Metformin (1mM), Phenformin (50uM) or in combination in normoxia (N) for 10 days 
(upper panel) and in hypoxia 1% O2 for 15 days (lower panel). 
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measured simultaneously. When 10 mM glucose was added to the medium CD147-/- 
cells showed a small but statistically significant reduction in ECAR when compared 
to wt cells while for OCR no significantly alterations were observed. Both wt and 
CD147-/- cells significantly decreased ECAR after MCT1/2 inhibitor AR-C155858 
injection. Finally, when we inhibited mitochondrial respiration with phenformin, and 
while OCR is reduced to low levels, wt cells almost maximize their ability to perform 
glycolysis but CD147-/- cells are not able to respond in the same levels as wt. These 
results suggest that A549 cells are sensitive to OXPHOS inhibition, and with the lack 
of MCTs, cells are not able to entirely switch to glycolysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3.6 A549 cells are more sensitive to phenformin   
 
Analyzing the clonogenicity results we detected that A549 wt cells were 
more sensitive to phenformin than to metformin in hypoxia. Measurement of OCR by 
Seahorse XF analyser indicated a 30% decrease of cellular respiration rate in cells 
exposed to phenformin when compared to metformin, suggesting that A549 
cells, are more sensible to phenformin (Figure 14A and B). Recently, Shackelford and 
co-workers 94 showed that LKB1 mutated cells were more sensitive to phenformin 
than metformin and that this effect was explained by the fact that with lacking 
phosphorylation of AMPK these cells accumulate defective mitochondria. Thus, we 
went to analyse the expression of AMPK. We observed that the A549 cells express 
Figure 13: Real time analysis of bioenergetic pathways in A549 wt and CD147 -/- cells. A: 
Extracellular acidification rate (ECAR) and B: oxygen consumption rate (OCR) measurement after 
injection of glucose (10 mM), MCT1i (1 µM) and phenformin (50 µM). 
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phospho-AMPK and the downstream target phospho-Acetyl-CoA Carboxylase 
(pACC) (Figure 14C). 
 
 
3.2.3.6 Combination of Glycolysis and OXPHOS inhibition decreases 
tumour growth in vivo 
To assess the effect of CD147 disruption in vivo, we compared the 
tumourigenecity of A549 wt and CD147-/- cells. Nude mice were s.c. injected with 
both cell populations. Surprisingly, CD147-/- cells generated bigger tumours than wt 
cells (Figure 13-black lines). However, phenformin greatly reduced tumour burdens 
in both cells with a major impact in CD147-/- cells (Figure 13A and B). These results 
reinforce the fact that a combined therapy, between glycolysis and OXPHOS, should 
be used as a strategy to treat lung cancer.  
Figure 14: A549 cells are more sensitive to phenformin. A and B:  Oxygen consumption rate measurement in 
A549 wt cells basal levels and after injection of glucose (10mM) and metformin (1mM) black column or 
phenformin (50 uM) grey column. A: cells without pre-treatment, B: cells were exposed to metformin or 
phenformin for 2h before measurement. C; Western blot for pACC, pAMPK and AMPK total in A549 cells. Cells 
were treated with phenformin for 1h and 3h with/without glucose. * Cells were maintained in glucose starvation 
for 2 hours extra before phenformin exposure. 
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Figure 15: Xenograft tumor growth of A549 wt (A) and CD147-/- cells (B) s.c. injected into the back of athymic 
nude mice. 6% sucrose with and without phenformin (200 mg/kg) was added to the drinking water for all the 
mice. Ten mice were studied per condition. 
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3.2.4 DISCUSSION 
 
Upregulation of glycolysis and adaptation to acidosis are key events in the 
transition from in situ to invasive cancer 4 and MCTs may play an important role 
through their involvement in exporting lactate 95. MCTs have been described to be 
upregulated in several cancers 26 however, there are still some controversies namely 
with regard to lung cancer 28,35,48. In the present study, we showed that MCTs are 
upregulated in tumour tissues when compared to non-tumoural adjacent tissue. 
Moreover, we detected MCT1 and MCT4 in the plasma membrane of all histological 
types studied. These results were in accordance with the ones of Koukourakis and co-
workers 35 however, in their work they did not describe the cellular localization of  the 
MCT staining. Interestingly, we found that MCT1 was overexpressed in squamous 
cell carcinoma subtype and MCT4 in the adenocarcinoma subtype, suggesting a 
different expression pattern between the histological types. However, due to the low 
number of cases this study should be replicated with a bigger number of cases to 
possible and better correlations. 
To understand the biological role of MCTs, we inhibited their activity. 
MCT1/2 AR-C155858 compound did not affect cell growth in either normoxia and 
hypoxia conditions. In normoxia, A549 cell lines mainly rely on oxidative 
phosphorylation than on glycolysis 96, thus inhibiting MCT1, even with low 
expression of MCT4 did not affect cell clonogenicity. In hypoxia, were OXPHOS is 
compromised, cells are also able to survive due to the HIF1α-induced MCT4. 
Although regulation of MCT expression is still far from being well understood, one of 
the best characterized MCT regulation mechanisms is through the co-expression with 
CD147. As there is no pharmacological inhibitor available for MCT4 and as previous 
results published 54 showed that CD147 major tumoural action is mediated by its 
action in energy metabolism controlling lactate transport, we decided to disrupt this 
chaperone to interfere with both lactate symporters. We observed that the KO of 
CD147 results in a decrease in MCT1 and MCT4 expressions. Regarding mRNA 
levels, we observed that these remained unchanged for MCT1 but increased 2-fold for 
MCT4 in the absence of CD147. The disruption of CD147 with the ZFN approach did 
not interfere with the transcription of MCTs. Regarding the MCT4 increase, the data 
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could suggest that in the absence of CD147, MCTs are synthesized but not trafficked 
out of the ER. 
Besides expression, we also observed that, under hypoxic conditions lactate 
efflux is compromised and a higher intracellular accumulation is observed in KO cells 
when compared with wt cells. These results confirmed the effect of CD147 silencing 
on the lactate transporters MCT1 and MCT4, as demonstrated by other groups in 
other cell lines 54. To note is the fact that, despite the KO of CD147 we still have a 
functional activity of MCT4 in these cells. These results revived again the idea that 
MCTs may have an additional chaperone to be trafficked to and active at the plasma 
membrane. Some studies suggest that CD44 can also play a role as a chaperone for 
MCTs. The widely distributed transmembrane glycoprotein CD44 and its main 
ligand, hyaluronan, were implicated in the regulation of lactate efflux and membrane 
localization of MCTs, in human breast and prostate carcinoma 28,46,88,97. In fact, CD44 
co-immunoprecipitates with MCT1, MCT4 and CD147 and co-localizes with these 
proteins at the plasma membrane. Perturbation of endogenous hyaluronan, using 
hyaluronan oligosaccharides, induced intracellular accumulation of CD44, MCT1 and 
MCT4. These observations suggest that constitutive interactions between hyaluronan, 
CD44 and CD147 can regulate localization and function of MCT1 and MCT4 97. In 
fact, a previous report from our group describe an association of MCT expression 
with CD44 in a small series of lung tumours 28. Moreover, the other basigin isoforms 
can also function as chaperones for MCTs, since ZFN targeted only isoform 2. Thus, 
further studies are needed to determine the mechanism by which MCTs could be 
trafficked and perform their activity in the absence of CD147. 
Several reports show that tumour cell lines with downregulation of CD147, 
via RNA interference, exhibit a decrease in cancer cell properties such as cell 
proliferation 62,98, invasiveness 79,80,98,99, anchorage-independent growth 79, and drug 
resistance 60,63,79 in vitro and a decrease in tumour growth in vivo 79,99 when compared 
to those expressing high levels of cell-surface CD147. Our results are not in 
accordance with some of the evidence as for example we did not observe a decrease 
in cell proliferation and cell viability on CD147 KO cells.  
Targeting a metabolic pathway can be tricky due to the high plasticity of the 
metabolic network of a cancer cell. Thus, we decided to test the effect on 
tumourigenicity inhibiting both glycolysis, by disrupting CD147, and OXPHOS. 
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The anti-diabetes biguanide compounds metformin and phenformin have 
been shown to inhibit complex I of the mitochondria 100,101, resulting in increases in 
intracellular AMP and ADP that bind to the gamma regulatory subunit of AMPK and 
trigger LKB1-dependent phosphorylation of AMPK 102. Consistent with activation of 
a low energy check-point, metformin treatment has been found to reduce tumour 
growth 103 and epidemiological studies revealed that diabetic patients taking 
metformin show a statistically significant reduced tumor incidence 104. Thus, this 
evidence point at both metformin and phenformin as promising anti-cancer agents. 
We evaluated the effect of both compounds on clonal growth and we observed that 
A549 cells are sensitive to them in normoxia. As shown by Wu and co-workers, A549 
cell line rely mainly on OXPHOS than on glycolysis 96. This evidence along with the 
results obtained from the seahorse analysis explained this sensitivity. In hypoxia, with 
the upregulation of MCT4, clonal growth remains unchanged for metformin and 
slightly decreased for phenformin. On the other hand, KO cells did not grow. The 
difference in response to both phenformin and metformin can be explained by the fact 
that phenformin is a 50-fold more potent inhibitor of mitochondrial complex I than 
metformin 100 and that uptake of metformin, but not phenformin, into tissue appears to 
require the expression of the Organic Cation Transporter 1 (OCT1), which is highly 
expressed in hepatocytes but not elsewhere reported 105. Moreover, Shackelford and 
co-workers showed that inactivation of the suppressor gene LKB1 dictated 
therapeutic response of NSCLC to phenformin 106. In this context, they showed that 
cells with mutated LKB1 (as A549 cell line) were more sensitive to phenformin and 
that this effect was dependent on AMPK activation. They hypothesized that without 
phosphorylation of AMPK trough LKB1, these cells lack the mitophagy process 
induced by the protein ULK1, a downstream target of AMPK. With this, cells 
accumulate defective mitochondria and therefore are unable to neutralize ROS, 
effectively leading to apoptosis. Taking this concept into account we went to analyse 
the expression of AMPK in A549 cell line. In contrast to other reports we detected 
expression of phospho-AMPK and the downstream target phospho-ACC under 
metabolic stress as glucose starvation or OXPHOS inhibition with phenformin. It is 
known that AMPK can also be activated by calcium/calmodulin-dependent protein 
kinase kinase 2 (CAMKK2) 107, however, further studies are needed. These results 
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have also led us to check the LKB1 status in our cell lines. Thus, studies on 
sequencing are underway to determine if LKB1 is mutated in these cells.  
In vitro studies of cells cultured in monolayer give information about cell-
autonomous metabolism however, they do not reflect the real physiological 
microenvironments in tumours. In vitro studies surprisingly showed that CD147 
disruption did not reduce tumour growth as shown by other groups 99,108. In fact, 
tumour growth increased approximately 4-fold when compared to wt cells. In the first 
place, these results could reflect a clonal growth effect of the clone used for this 
experiment. However, in vitro studies showed that these KO cells have the same 
proliferation rates as wt cells. Importantly and besides these results, we observed that 
phenformin drastically inhibited tumour growth, having a stronger impact in CD147-/- 
cells when compared to wt cells. Further experiments in vivo will be undertaken 
comparing wt cells and two CD147 -/- clones to elucidate the real contribution of 
CD147 KO to tumourigenesis. 
The results obtained by MCT/CD147 inhibition are promising however, we 
are far from assume MCTs as effective targets for cancer therapy. Thus, more efforts 
are needed to prove that inhibition of metabolism, more specifically lactate transport, 
may be an alternative therapeutic strategy to use in the treatment of certain types of 
cancer. Therefore, the present work is an attempt to provide new data supporting the 
exploitation of MCTs/CD147 as targets in lung cancer therapy. 
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4.1 General discussion 
 
In the light of the major findings achieved throughout this thesis, in the 
present section a general discussion will be given on how these findings can 
contribute to the link between basic research and the clinical scenery.  
  
 
 
4.1.2 Overview on the contribution to the state of the art 
  
 
4.1.2.1 Lung development 
 
Embryonic development is characterized by the spatial and temporal 
differentiation of stem cells, leading to the generation of tissue diversity. This process 
of differentiation is dictated by microenvironmental mediators such as morphogen 
gradients and oxygen availability 1–3. Hypoxic environment favours anaerobic 
glycolysis 4–6 and this metabolic phenotype is characterized by the metabolization of 
pyruvate into lactate 7 which is then exported by MCTs to the extracellular milieu to 
avoid a decrease in the intracellular pH (pHi) 8. Although the contribution of MCTs to 
the glycolytic and acidic phenotype of tumours is well studied 8,9, their contribution to 
the embryo development is still not clear. In the Chapter 2, we provided evidence that 
could give some contribution for the understanding of the metabolic phenotype that 
lung developing cells harbour. Several studies have already suggested that embryos, 
as proliferating cells, express a metabolic phenotype similar to that of cancer cells 7. 
Firstly, by the expression of the hypoxia marker CAIX, we propose that lung cells 
develop in an environment with low O2 levels. Moreover, we showed that both 
MCT1/4 isoforms, CD147 and glucose transporters are expressed throughout the lung 
development phases, suggesting that these molecules are important for lung 
morphogenesis. Importantly, we described the expression pattern of these molecules 
in the different cells subtypes of the developing embryo. Stimulation of glycolytic 
metabolism in cells leads to lactate production. However, lactate is more than merely 
a by-product of glycolysis as it can be used as a metabolic fuel by oxidative cancer 
cells 10–12. The branching morphogenesis of the lung growth process occurs through 
fundamental cross-talk interactions between epithelial and mesenchymal tissues, 
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involving a multitude of effectors 13,14. Can we suggest a lactate shuttle between 
epithelial and mesenchymal cells as observed in other systems 10,15–17? In the early 
phases of lung development epithelial cells express mainly GLUT1 and MCT4 and 
mesenchymal cells express MCT1. This led us to hypothesize that epithelial cells are 
glycolytic and produce lactate that could be utilized by mesenchymal cells. Along 
development, mesenchymal cells differentiate and the expression of MCTs is 
restricted to the alveolar and bronchial epithelia (Figure 1). However, studies are 
needed to support this theory. More sensitive techniques can be employed, such as 
single cell qPCR on laser-dissected cells in order to quantify the expression of each 
target in each cell population. 
Pulmonary development is a complex process and two mechanisms, growth 
and maturation, are crucial for the developing lung 18–20. Cell growth occurs through a 
cross-talk between epithelial and mesenchymal tissues, airway and vasculature, 
involving several effectors including growth factors, hormones, extracellular matrix 
interactions, and mechanical stimuli 13,21. During the last decades, the regulating 
mechanisms of lung growth have been unravelled 18,22.  
In Chapter 2 we also showed the inhibition of MCTs in lung morphogenesis, 
using rat fetal lung explant models cultured under CHC exposure. We observed that 
lung branching was inhibited with increasing concentrations of CHC, suggesting that 
MCTs are required for lung morphogenesis. The main limitation to this work is the 
fact that the most widely used MCTs inhibitors may also have other targets in the cell. 
For example, CHC, the inhibitor used in this work, can also inhibit the mitochondrial 
pyruvate transporter 23,24. This was described by Halestrap and co-workers in 1974 24, 
however in this study they used isolated mitochondria. On one hand, there are no 
studies reporting the entry of CHC into cells and, on the other hand, there is evidence 
showing that CHC acts only outside the cell 24–27. Thus, we believe that the effect of 
CHC in our model is mediated by inhibition of MCT activity at the plasma 
membrane. However, further experiments should be performed to clarify the true 
contribution of MCT inhibition in lung branching. Experiments with the specific 
inhibitor of MCT1/2 from AstraZeneca 28 or even RNA interference approaches could 
be used. Other fact that should be taken into account was the hiperoxic conditions 
where explant cultures were performed. In fact, beyond the controversy existent in the 
literature about the levels of oxygen during gestation, the truth is that several evidence 
point to the existence of a hypoxic environment. However, due to the impossibility to 
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have adequate equipment to cultivate explants with low levels of oxygen, we 
performed the cultures under normoxic conditions (21% O2), which may not mimic 
the real in vivo environment. 
 
 
Although the role of MCTs in lung morphogenesis is still far from being well 
understood, with this study we showed that MCT inhibition disrupts lung branching, 
suggesting the dependence of these transporters for lung development. Embryonic 
developmental is strongly influenced by oxygen availability in the environment 29. 
From our results, we hypothesize that lung embryonic cells are able to survive in 
hypoxia environments adopting a metabolic phenotype to supply energy and that 
MCTs/hypoxia may have different and specific functions in epithelial differentiation 
and vascular morphogenesis. Nevertheless, further studies are needed to better 
characterize this metabolic phenotype during lung differentiation.  
The knowledge of all effectors and regulators of lung development is of great 
Figure 1: Schematic model for the lactate shuttle between epithelial cells and mesenchymal cells 
hypothesized in this work. 
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importance 30. The better we know and understand the normal physiology of the 
developing lung, better we will perceive lung development defects and also adult lung 
diseases 31. 
 
4.1.2.2 Lung cancer 
Upregulation of glycolysis and adaptation to acidosis are key events of 
invasion and metastization cancer 32–34 and MCTs play an important role through their 
involvement in exporting lactate 27,35–37. MCTs have been described to be upregulated 
in several cancers 8, however, there are still some controversies namely with regard to 
lung cancer 38–40. In the present study we showed that MCTs are upregulated in lung 
tumour tissues when compared to non-tumoural adjacent tissue. Moreover, we 
detected MCT1, MCT4 and CD147 at the plasma membrane of all histological types.  
One limitation of this work was the low number of lung cancer samples obtained from 
the hospital files to perform this retrospective study. In order to substantiate these 
results, a higher number of cases should be collect with the respective clinic-
pathological data for further correlations.  
To understand the biological role of MCTs we inhibited their activity, 
disrupting the chaperone CD147 to interfere with both lactate symporters, MCT1 and 
MCT4.  
For the accomplishment of this work we used a class of engineered DNA-
binding proteins named zinc finger nucleases that create double strand breaks in a 
specific gene 42. With this technique we permanently knocked-out CD147 in the lung 
adenocarcinoma cell line A549.  The KO of a gene is used to understand the role of a 
specific gene 43. With this work, we tried to understand the role of CD147 on the 
inhibition of lactate transport. However, our results were not in accordance with 
several reports that study the effect CD147 downregulation, via RNA interference 
(iRNA). Inhibition of CD147 by iRNA leads to a decrease in cancer cell proliferation 
44,45, invasiveness 45–48, anchorage-independent growth 46 in vitro and a decrease in 
tumour growth 46,47 in vivo when compared to cells expressing high levels of cell-
surface CD147. Our results are not in complete agreement with the latter results, as 
for example we did not observe a decrease in cell proliferation and cell viability with 
CD147 KO cells in vitro. Moreover, we observed an increase in tumour growth with 
CD147-/- cells. So far, we do not have any justification for this fact. A characteristic of 
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this technique is that only the cells that are able to grow without CD147 will form 
clones and be selected for further characterization. Moreover, during clonal growth, 
cells may have time to adopt an advantageous phenotype to overcome the absence of 
this molecule and thus maintain the same proliferation rates as wt cells. Thus, with 
this approach we were able to decrease MCTs expression and activity, but this was 
not enough to kill cancer cells, probably due to the high plasticity of metabolic 
network inherent to these cells. Thus, a more drastic treatment should be adopted and 
tested. We proved that inhibiting two important bioenergetic pathways, glycolysis and 
mitochondrial respiration, decreases cell growth in vivo and in vitro. 
Therefore, the work presented in Chapter 3 provides new data supporting in 
the exploitation of MCTs/CD147 as targets in lung cancer therapy. A better 
understanding of the molecular mechanisms driving lung tumourigenesis is crucial 
and will certainly contribute to the developing of new pharmacologic treatments. 
However, further studies involving the development of specific MCTs/Bsg blockers 
in particular, are urgently needed.  
 
 
4.1.2.3 MCTs as promising therapeutic targets 
With the revival of Warburg effect hypothesis, several reports have been 
published in the past years 49–52.  Many intervenients have been associated with 
cellular metabolic phenotype and MCT expression has been described in several solid 
tumours 8. However, functional studies characterizing the overall role of MCTs as 
therapeutic agents are still very scarce. This fact may be due to the limitation on MCT 
inhibitors. The classical drugs used to inhibit MCT activity are not specific. Some 
studies have been published showing the effect of MCT inhibition by CHC 36,53,54 or 
DIDS 55,56, among others 56–58 however, these drugs also inhibit other targets in the 
cell 59,60. In a search for immunosuppressive drugs, MCT1 was identified as a 
promisor target 61 and thus, specific inhibitors were designed by AstraZeneca 62,63. 
Different compounds were developed, some inhibiting MCT1 64 and others  both 
MCT1 and MCT2 28.  Moreover, direct strategies are the use of siRNAs, which have 
already shown promising results in other models however, the use of this approach in 
cancer therapy needs to be studied cautiously. 
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4.1.2.4 Evidence for MCT regulation 
In this thesis, MCT expression was characterized of in a small series of 
human lung tumours, providing evidence for MCT upregulation in these cancer cells. 
These and similar results observed in other tumour types 36,53,65–67 lead us to suggest 
that these transporters are promising therapeutic targets for cancer therapy, however, 
further studies are needed. Importantly, although CD147 is described to be associated 
with both MCT1 and MCT4 the fact is that, besides the KO of CD147 we still have a 
functional activity of MCT4 in these cells. These results revived the idea that MCTs 
may have other chaperones to be trafficked and active ate the plasma membrane. 
Some studies suggest that CD44 can also play a role as a chaperone for MCTs. The 
widely distributed transmembrane glycoprotein CD44 and its main ligand, 
hyaluronan, were implicated in the regulation of lactate efflux and membrane 
localization of MCTs, in human breast and prostate carcinoma 38,68–70. In fact, CD44 
co-immunoprecipitates with MCT1, MCT4 and CD147 and co-localizes with these 
proteins in the plasma membrane. These observations suggest that constitutive 
interactions between hyaluronan, CD44 and CD147 regulate MCT localization and 
function of MCT1 and MCT4 69. In fact, a previously report from our group showed 
an association of MCTs expression with CD44 in a small series of lung tumour 38. 
Further, in the tumour screening, this absence of CD147 was not overcome by CD44. 
Also, other basigin isoforms can play a role as chaperones for MCTs. The ZFN 
plasmids only target exon 2 that is common to both isoform 1 and 2 but not to 3 and 
4. Thus, further studies are needed to determine the mechanism by which MCTs are 
trafficked and perform their activity in the absence of CD147. These findings suggest 
that a not yet identified chaperone may be involved in MCT trafficking to the plasma 
membrane.  
 
 
4.1.3 How does a tumor compare to an embryo? 
 
Several groups of genes that drive embryogenesis normally go silent during 
the rest of life, but these genetic programs can be turn on in many tumour cells 71. 
Moreover, some reports document that a molecular signature of lung cancer 
recapitulates lung development 72,73. Indeed, they hypothesized that a subset of a 
genes are associated with the different histologic types of lung cancer. Lung 
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adenocarcinoma tumours showed a similar signature of the earliest embryonic 
development stages, while squamous cell carcinoma type recapitulates later 
development events 72–74.  Exploring the results obtained in this thesis and with the 
background that hypoxia is a shared event in both embryogenesis and tumourigenesis 
process, we suggest that MCTs have a crucial role in both processes. However, our 
results have limitations and a clear relationship between lung development and lung 
cancer cannot yet be determined. 
The idea of shared molecular mechanisms between tumours and embryos is 
not new. Thus, with a better understanding of the physiologic mechanisms governing 
lung development, comes the possibility to identify genes/pathways involved in 
tumourigenesis, opening new opportunities for treatment. 
 
 
 
4.2 Conclusion and future perspectives 
 
In general, the results here presented suggest an important role of MCTs in the 
physiology of the developing lung and in the phenotype of lung cancer. Besides the 
achievements of this work, many other doors are now open that should be explored.  
Regarding lung development, a more specific inhibition should be use in rat 
explant cultures to determine the true role of MCTs in lung branching. Moreover, to 
understand the window of action of MCTs in lung morphogenesis, MCTs inhibitors 
should be tested at different time points to assess time-specific effects. 
In lung cancer, characterization of MCTs expression in more comprehensive 
tumour series would be of great value, as additional promising results are anticipated. 
Further, correlations with the clinic-pathological data are anticipated, since MCT1 
and/or MCT4 have been already reported to be associated with poor prognostic 
variables, invasiveness, aggressiveness and other tumour features in other tumour 
types 36,65,66,75,76.   
Since with the KO of CD147 we were not able to completely inhibit both 
MCT1 and MCT4, and with the lack of a pharmacologic inhibitor specific for MCT4, 
a similar approach using zinc finger nuclease could be done. Moreover, these studies 
could be complemented in a different lung cell line with a more glycolytic phenotype. 
MCTs are pointed as important molecular players in cancer and promising therapeutic 
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targets however, it should be always kept in mind that the main goal to inhibit MCTs 
is the future clinical application, so MCT inhibitors should be subjected to clinical 
studies, including the study of their cytotoxic effects. As possible alternative 
chaperones are suggested to be involved in MCT trafficking to the plasma membrane, 
additional studies assessing protein interactions with MCTs will provide new 
knowledge on MCT regulation. For that, databases of protein interactions would be an 
important tool to explore for the first hints. 
In conclusion, the results herein presented provide evidence for the 
involvement of MCTs in lung development and encourage the exploitation of MCTs, 
as potential targets for cancer therapy. 
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CD147/Basigin disruption using Zinc Finger Nuclease technology 
Sara Granja, Ibtissam Marchiq, Fatima Baltazar and Jacques Pouysségur  
 
Summary 
Zinc Finger Nucleases (ZFNs) are reagents that induce DNA double-strand breaks (DSDs) at 
specific sites that can be repaired by non-homologous end joining (NHEJ), inducing 
alterations in the genome. This strategy has enabled highly efficient gene disruption in 
numerous cell types and model organisms opening a door for new therapeutic applications. 
Here, we describe the disruption of CD147/Basigin by this technique in a human cancer cell 
line. 
 
 Key words: DNA double-strand breaks, gene targeting, Knockout, Zinc Finger 
Nuclease  
 
  1. Introduction  
Zinc-Finger Nucleases (ZFNs) are a class of engineered DNA-
binding proteins that have redefined genome engineering. The ZFNs 
plasmids bind a specific DNA sequence, inducing a double strand 
break (DSB). This break is repaired by the non-perfect endogenous 
repair mechanism called non-homologous end joining (NHEJ). The 
DBS will be misrepaired by the addition and/or deletion of 
nucleotides. This disruption results, in multiple mutations that could 
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induce non-sense gene products in both alleles leading to a specific 
gene knockout. The ZFNs structure consists of a DNA binding 
domain – Zinc Finger Protein (ZFP) - linked to a nuclease domain of 
the FOK1 restriction enzyme1.	  
The ZFP region contains a tandem array of Cys2-His2 fingers that 
each recognizes 3bp of DNA. This domain can have from 3 to 6 
fingers binding to a target of 9bp to 18bp respectively. The catalytic 
domain composed by the enzyme FOK1 requires dimerization to cut, 
thus a pair of ZFNs is required. The dimerization restriction avoids 
cleavage at single binding sites2. Genomic modification with ZFN 
was first described more then 10 years ago, and a huge progress in 
this technique was observed in the last few years.  This is now a well 
established method in several organisms 3. ZFN-targeted mutagenesis 
has been achieved in Zebrafish 4, rat embryo 5, mouse 6, sea urchin 7, 
frog 8, Drosophila 9, plants10, C. elegans 11 and human cells 12. 	  
Applications of ZFNs represent a complementary strategy to siRNA 
enabling highly efficient gene disruption in human cells and opening 
a door for new therapeutic applications 1. The aim of our study is to 
understand the tumorigenic influence of lactate transport by 
monocarboxylate transporters (MCT1 and MCT4) in human cells by 
inhibiting their chaperone CD147/Basigin. Here, we demonstrate an 
efficient disruption of the gene CD147/Basigin in the A549 human 
lung adenocarcinoma cell line. A similar procedure has been already 
described in our laboratory in the LS174T colon adenocarcinoma cell 
line12. In this section we show a protocol used to knockout 
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CD147/Basigin in A549 cell line.  
 
2. Materials   
2.1 ZFN components  
 
 
1. CompoZr Knockout Zinc Finger Nucleases (CKOZFN1227-
1KT): ZFN plasmids targeting basigin exon 2 encoding signal 
peptide of basigin splice variants 1 and 2 were designed and 
obtained from Sigma-Aldrich. Store at -80 °C.  
2. Each kit contains besides the plasmid DNA for each ZFN, a pair 
of primers (forward and reverse) for screening of mutations in 
the DNA locus. Make aliquots of 10 uM. Store at -20°C.     
 
2.2 Plasmid 
transformation and 
isolation components 
 
1. Chemically Competent E. coli 
2. LB medium: Prepare according to the manufacturer’s 
3. Kanamycin  
4. QUIAGEN Plasmid isolation/purification Maxi Kit 
 
2.2 Cell line  
1. A549 human adenocarcinoma cell line. 
2. Culture media: DMEM supplemented with 10% inactivated 
FCS, penicillin (10 µg/mL) and streptomycin (50 µg/mL). 
2.3 Reagents  
1. PBS-1% serum (see note 1) 
2. JetPRIME® DNA & siRNA Transfection Reagent from 
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Polyplus-transfection SA. Store at 4°C (See note 2) 
 
 
2.4 Antibodies  
1. Mouse monoclonal EMMPRIN antibody (Santa Cruz 
Biotechnology - sc-21746). Store at 4°C. 
2. Mouse monoclonal antibody EMMPRIN/CD147 (R&D 
Systems; MAB972). Store at -20°C. 
3. R-Phycoerythrin-conjugated AffiniPure Goat Anti- Mouse IgG 
(Jackson ImmunoResearch; no. 115–115-164) Store at 4°C in 
the dark. 
4. Horseradish peroxidase anti-mouse antibody (Promega). Store 
at 4°C. 
 
3. Methods  
3.1 Plasmid 
transformation and 
isolation 
This protocol should be carried out on ice unless otherwise is 
specified. 1. Transform the ZFNs plasmids into a chemically competent E. 
coli cells. 2. Add 50 ng/µl of each plasmid into a vial of chemically 
competent E. coli cells separately 3. Incubate on ice for 30 min. 4. Subject the cells to a thermal shock at 42 °C for 45 seconds and 
place them on ice for 2 min. 5. Transfer into 900 µl of pre-warmed LB medium and placed to 
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shake horizontally (200 rpm) for 1h at 37 °C. 6. Plated 10-100 µl from each transformation on a plate with LB 
agar medium containing the antibiotic for selection (see note 3) 
and incubate overnight at 37°C (see note 4) 7. Pick isolated colonies and subculture them in a tube containing 
5 ml of LB medium with antibiotic of selection (see note 3). 
Allow growing overnight (orbital incubator, 37 °C, 225 rpm). 8. Isolate the plasmid with the QUIAGEN Plasmid isolation Maxi 
Kit. (See note 5) 
 
4.2 Cell line 
transfection  
 
All procedures should be carried out under laminar air-flow 
chamber. (see note 6 and 7) 
 
1. Seed A549 cells with 60% confluence (1x10^6 cells) in a 100 
mm diameter dish.  
2. After 24h transfect the cells using JetPRIME DNA transfection 
reagent. 
3. Dilute 10 µg of DNA (5µg of each ZFN plasmid) into 500 µl 
jetPRIME® buffer.  Mix by vortexing. (see note 8) 
4. Add 20 µl of jetPRIME reagent vortex and spin down briefly. 
Incubate the complex for 10 min. 
5. Add 500 µl of the complex (drop by drop) into the cells and 
mix gently. 
6. Replace the transfection medium after 6 hours by fresh 
medium. 
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7. Culture the cells for one to two weeks in a humidified 
atmosphere of 5% CO2 at 37 °C. 
 
 
5.3 Fluorescence-
activated cell sorting 
(FACS) 
 
All procedures should be carried out under a laminar airflow 
chamber. During incubation times place the cells and PBS 1% 
serum on ice. Cell clumps should be avoid by resuspending the cells 
during long incubations. (See note 9) 
 
1. Place up to 1 X 10^6 cells in a tube. Centrifuge for 5 min at 
1200 rpm. Discharge supernatant (see note 10) 
2. Wash once with cold PBS 1% serum. Centrifuge for 5 min at 
1200 rpm. Discharge supernatant. 
3. Per 1 x 10^6 cells add 100 µl of CD147 antibody (sc-21746) 
diluted 1/100 in PBS1x 1% FCS. Incubate for 30 min on ice. 
(See note 11) 
4. Wash once with PBS1x FBS 1% by centrifugation at 1200rpm 
for 5 min. Aspirate supernatant. 
5. Incubate the cells with the R-Phycoerythrin-conjugated 
AffiniPure Goat Anti- Mouse IgG (Jackson ImmunoResearch; 
no. 115–115-164) diluted 1/1000 in PBS 1% serum. Incubate 
for 30 min on ice. (See Note 12) 
6. Wash once with PBS1x FCS 1% by centrifugation at 1200 rpm 
for 5 min. Aspirate supernatant. 
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7. Add 500 µl PBS 3% serum 1mM EDTA and filter the samples 
in a FACS tube.  
8. Select and sort CD147 negative cells and plate one cell per well 
in a 96 well plate with 100 µl DMEM supplemented with 10% 
inactivated FCS and penicillin (10 µg/mL).  Allow the cells to 
grow in a humidified atmosphere of 5% CO2 at 37 °C. (see note 
13 and 14) 
9. After growing in the 96 well plate, each clone should be 
subculture for the screening of CD147/Basigin cells. (See note 
15) 
 
4.3 Screening of 
CD147/Basigin 
cells 
 
1. Freeze some cells of each clone in a vial with serum 1% 
DMSO. (See note 16) 
2. Subculture each clone in two diferent wells. Add 1mM 
metformin to on well (for a pre-selection see note 17) and let 
the other well growing to propagate the clone.  
3. Extract proteins from the clones that die in the pre-selection 
with metformin.  
4. Perform a Western blot to analyse the expression of 
CD147/Basigin in these clones. (See note 18) 
5. Select the clones that were completely negative by western 
blot. (See note 19) 
6. Extract genomic DNA from your cells.  
7. Confirm the gene disruption performing a PCR with the 
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primers provided by ZFNs kit. (See note 20). 
8. Send to sequence your PCR products (see note 21). 
   
 
 
 
 
 
4. Note  
1. Prepare this solution immediately before use. The PBS should 
be cold and sterile.  
2. The delivery of ZFNs plasmids into the cells could be done 
with diferent transfection protocols. The choice of transfection 
technology can strongly influence transfection efficiency. From 
all the protocols we tested we chose this transfection protocol 
because it is fast and easy to perform, cause minimal 
cytotoxicity for this cell line and required smaller amount of 
DNA to transfect. 
3. The appropriate antibiotic is described in the datasheet of the 
zinc finger plasmids send by the manufacture. In this specific 
case the antibiotic of selection used was Kanamycin.  
4. Plate two different volumes to ensure that at least one plate will 
Figure 1: Western blot analysis of Bsg in transfected cells. A549 wt 
cells (lane 1,2 and 3) Bsg+/- cells (lane 4 and 5) and Bsg-/- cells (lane 6-
17) exposed to normoxia (N) and hypoxia 1% O2 (H) . ARD1 used as a 
loading control. 
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have well spaced colonies. 
5. QIAGEN-tip 500 protocol from the kit was followed as 
described by the manufacturer. In the end, DNA was 
redissolved in approximately 100 µl 
6. Aseptic technique and the proper use of laboratory equipment 
are essential when working with cell cultures. Always use 
sterile equipment and reagents, and wash hands, reagent bottles, 
and work surfaces with surfanios or 70% ethanol before starting 
the work. 
7. Health and viability of the cell line can influence the efficacy of 
the transfection. Check this before you start your experiment. 
8. In order to control if the cells internalized the plasmids you can 
also introduce during transfection a GFP plasmid (0,5 µg). This 
will give you the information that the transfection went good 
and cells were properly transfected. 
9. This approach can not be used for all molecules. We need the 
cells viable so the antibody should be able to recognize our 
protein without internalization. In case this is not possible 
transfection with GFP plasmid should be performed and the 
cells should be analysed by FACS after 48h of transfection. In 
this case cells positive for GFP should be sorted.  
10. Try to stain the maximum of cells possible to have the number 
of events necessary for FACS analysis (around 6x10^6 cells). 
Use separate tubes for staining of 1 X 10^6 each to make sure 
that all cells are uniformly stained. 
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11. Do not to forget to have one tube as negative control for 
CD147/basigin expression. This tube should not be incubated 
with primary antibody. Incubation time can vary between 30 
min to 1h. Do not forget to ressuspend the cells to avoid 
deposition of cells that could lead to an inefficient staining. 
12. Protect all the tubes from light to not degrade the fluorochrome.  
13. There are some cell lines that are not able to growth as single 
cells. For that, 100 µl of conditioned media could be added to 
the well. The growth factors available in the conditioned media 
can help cells to attach and growth 
14. As single cells (clones) are plated in each well, cells will need 
approximately up 3 to 4 weeks to growth and generate a cell 
population. Thus, after 2 days of sorting the cells make up the 
well volume to 200 ml with fresh medium to ensure enough 
nutrients for cell growth. 
15. Clones with different size and phenotypes are obtained. You 
should not forget that besides the selection of negative cells 
stained by the cell sorter, different cells are also originated as: 
heterozygotic cells (with only one allele cut), homozygotic cells 
(with the two alleles cut) and cells that have not be transfected. 
Each clone should be identified as desired (for example 
1,2,3...). Select the maximum of clones and subculture them. 
This step is critic. Manipulate carefully your cells to avoid 
contamination. 
16. Freezing media depends on the cell line. Normally consists in 
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Growth medium (RPMI, DMEM, etc.) containing 5-10% FBS  
17. Metformin is a drug from biguanid class that impaired 
oxidative phosphorylation. We perform this treatment as a pre-
selection for putative negative clones. The ones that have 
disruption of CD147/basigin and consequently a decrease in 
lactate export (inhibiting glycolysis), will die after blocking 
respiration. 
18. The Western blot can vary according to the lab. In our lab and 
for this study we separate 40 µg of protein on a 8% SDS 
polyacrylamide gels and transferred onto polyvinylidene 
difluoride membranes (Millipore). The membranes were 
incubated with the monoclonal antibody of Bsg/CD147 (R&D 
Systems; MAB972) diluted 1/1000 and after with a horseradish 
peroxidase anti-mouse antibody (Promega) diluted 1/5000.  
Bands were detected with ECL (Amersham Biosciences or 
Millipore).	   
19. Select only 5 to 8 clones to further characterize decreasing the 
amount of cells to manipulate. 
20. PCR reaction was carried out in a total volume of 20 µl, 
consisting of 200 ng of gDNA, 0.5 µM of both sense and anti-
sense primers (sent with the ZFN kit), 200 µM of dNTPs, 1,5 
mM of MgSO4, 1 × Taq Buffer and 10 U of KOD hot start 
DNA polymerase (all the reagents from Novagene). The 
reaction consisted of an initial denaturation at 95 °C for 3 min, 
followed by 31 cycles with denaturation at 95 °C for 10 s, 
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annealing at 68 °C for 30 s and extension at 68 °C for 30 s, 
followed by a final extension 3 min at 68 °C.  
21. New primers targeting a smaller fragment in the targeted area 
should be designed and synthetized. These new nested PCR 
products should be sent for sequencing to confirm the 
disruption of your gene in your clones.  
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